



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 401/04, 401/14, A61K 31/505		A1	(11) International Publication Number: WO 98/18782 (43) International Publication Date: 7 May 1998 (07.05.98)
<p>(21) International Application Number: PCT/GB97/02949</p> <p>(22) International Filing Date: 27 October 1997 (27.10.97)</p> <p>(30) Priority Data: 9622363.1 28 October 1996 (28.10.96) GB</p> <p>(71) Applicant (for all designated States except US): CELLTECH THERAPEUTICS LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): DAVIS, Peter, David [GB/GB]; 10 Astor Park, Ashton Rowant, Oxford OX9 53W (GB). MOFFAT, David, Festus, Charles [GB/GB]; 14 Lonsdale Way, Holypot, Maidenhead, Berkshire SL6 2YX (GB). BATCHELOR, Mark, James [GB/GB]; 13 Delamare Way, Cumnor Hill, Oxford OX2 9HZ (GB). HUTCHINGS, Martin, Clive [GB/GB]; 93 Roycroft Lane, Barkham, Wokingham, Berkshire RG40 4HN (GB). PARRY, David, Mark [GB/GB]; 9 Troutbeck Close, Twyford, Berkshire RG10 9DE (GB).</p> <p>(74) Agent: HALLYBONE, Huw, George; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION</p> <p style="text-align: center;"> (1) </p> <p>(57) Abstract</p> <p>Compounds of general formula (1) are described wherein: Ar is an optionally substituted aromatic group; R² is a hydrogen or halogen atom or a group -X¹-R^{2a} where X¹ is a direct bond or a linker atom or group, and R^{2a} is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R³ is an optionally substituted heterocycloalkyl group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective protein tyrosine kinase inhibitors, particularly the kinases ZAP-70 and syk and are of use in the prophylaxis and treatment of immune or allergic diseases and diseases involving inappropriate platelet activation.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR
PREPARATION**

This invention relates to 2-pyrimidineamine derivatives, to processes for
5 their preparation, to pharmaceutical compositions containing them, and to
their use in medicine.

Protein kinases participate in the signalling events which control the
activation, growth and differentiation of cells in response to extracellular
10 mediators and to changes in the environment. In general, these kinases
fall into two groups; those which preferentially phosphorylate serine
and/or threonine residues and those which preferentially phosphorylate
tyrosine residues [Hanks, S K, Hunter T, FASEB. J. 9, 576-596 (1995)].
The serine/threonine kinases include for example, protein kinase C
15 isoforms [Newton A C, J. Biol. Chem. 270, 28495-28498 (1995)] and a
group of cyclin-dependent kinases such as cdc2 [Pines J, Trends in
Biochemical Sciences 18, 195-197 (1995)]. The tyrosine kinases include
membrane-spanning growth factor receptors such as the epidermal growth
factor receptor [Iwashita S and Kobayashi M. Cellular Signalling 4, 123-
20 132 (1992)], and cytosolic non-receptor kinases such as p56^{lck} p59fyn
ZAP-70 and csk kinases [Chan C *et al* Ann. Rev. Immunol. 12, 555-592
(1994)].


Inappropriately high protein kinase activity has been implicated in many
25 diseases resulting from abnormal cellular function. This might arise either
directly or indirectly, for example by failure of the proper control
mechanisms for the kinase, related for example to mutation,
overexpression or inappropriate activation of the enzyme; or by over- or
underproduction of cytokines or growth factors also participating in the
30 transduction of signal upstream or downstream of the kinase. In all of
these instances, selective inhibition of the action of the kinase might be
expected to have a beneficial effect.

We have now found a series of 2-pyrimidineamine derivatives which are
35 potent and selective inhibitors of the protein tyrosine kinases ZAP-70 and

syk. The ZAP-70 kinase is involved in the transduction of signals from the T-cell receptor and thus in the activation of T-cells during the immune response. The closely related kinase syk is involved in signalling from the B-cell receptor and thus in the activation of B-cells during the immune response [van Oers N S, Weiss A, *Seminars in Immunology*, 7, 227-236, (1995)] and is also involved in signalling from the Fc epsilon RI, the high-affinity IgE receptor present on mast cells [Zhang J, *et al*, *J. Exp. Med.* 184, 71-79 (1996)] and in the survival of eosinophils mediated by IL5 and GM-CSF [Yousefi S, *et al* *J. Exp. Med.* 183, 1407-1414, (1996)]. Syk is further involved in the activation of platelets stimulated via the low-affinity IgG receptor (Fc gamma-RIIA) or stimulated by collagen [Yanaga F, *et al*, *Biochem. J.* 311, (Pt. 2) 471-478, (1995)].

The compounds of the invention are thus of use in the prophylaxis and treatment of immune diseases (including autoimmune diseases and transplant rejection), allergic diseases involving mast cells or eosinophils, and diseases involving inappropriate platelet activation.

Thus, according to one aspect of the invention, we provide a compound of formula (1):



wherein Ar is an optionally substituted aromatic group;
 25 R² is a hydrogen or halogen atom or a group -X¹-R^{2a} where X¹ is a direct bond or a linker atom or group, and R^{2a} is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group;
 R³ is an optionally substituted heterocycloalkyl group;
 and the salts, solvates, hydrates and N-oxides thereof.

It will be appreciated that in the compounds of formula (1) the pyrimidine and R³ groups may be attached to any ring carbon atom of the pyridyl group, provided always that they are not both attached to the same carbon atom.

5

The group R² in compounds according to the invention may be for example a hydrogen or halogen atom such as a fluorine, chlorine, bromine or iodine atom, or a group -X¹-R^{2a} where X¹ is a direct bond or linker atom or group, and R^{2a} is an optionally substituted straight or branched chain 10 alkyl, alkenyl or alkynyl group.

Linker atoms represented by X¹ when present in compounds of formula (1) include -O- or -S- atoms. When X¹ is a linker group it may be for example a -C(O)-, -C(S)-, -S(O)-, -S(O)₂-, -N(R⁷)- [where R⁷ is a hydrogen 15 atom or a C₁₋₆ alkyl, e.g. methyl or ethyl, group], -CON(R⁷)-, -OC(O)N(R⁷)-, -CSN(R⁷)-, -N(R⁷)CO-, -N(R⁷)C(O)O-, -N(R⁷)CS-, -SON(R⁷), -SO₂N(R⁷), -N(R⁷)SO₂-, -N(R⁷)CON(R⁷)-, -N(R⁷)CSN(R⁷)-, -N(R⁷)SON(R⁷)- or -N(R⁷)SO₂N(R⁷) group.

20 When R^{2a} is present in compounds of the invention it may be for example an optionally substituted straight or branched chain C₁₋₆ alkyl, e.g. C₁₋₃ alkyl, C₂₋₆ alkenyl e.g. C₂₋₄ alkenyl or C₂₋₆ alkynyl e.g. C₂₋₄ alkynyl group. Particular examples of such groups include optionally substituted -CH₃, -CH₂CH₃, -(CH₂)₂CH₃, -CH(CH₃)₂, -(CH₂)₃CH₃, -CH(CH₃)CH₂CH₃, 25 -CH₂CH(CH₃)₂, -C(CH₃)₃, -(CH₂)₄CH₃, -(CH₂)₅CH₃, -CHCH₂, -CHCHCH₃, -CH₂CHCH₂, -CHCHCH₂CH₃, -CH₂CHCHCH₃, -(CH₂)₂CHCH₂, -CCH, -CCCH₃, -CH₂CCH, -CCCH₂CH₃, -CH₂CCCH₃ or -(CH₂)₂CCH groups. The optional substituents which may be present on these groups include one, two, three or more substituents selected from 30 halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or hydroxyl, C₁₋₆ alkoxy, e.g. methoxy or ethoxy, thiol, C₁₋₆ alkylthio, e.g. methylthio or ethylthio, amino C₁₋₆ alkylamino, e.g. methylamino or ethylamino, or C₁₋₆ dialkylamino, e.g. dimethylamino or diethylamino groups.

35

R³ in compounds of formula (1) may be for example an optionally substituted heteroC₃₋₇cycloalkyl group containing one or two oxygen, or sulphur atoms or nitrogen containing groups. The heterocycloalkyl group may be attached to the remainder of the molecule of formula (1) through 5 any of its carbon or, where present, nitrogen atoms as appropriate.

Where desired, any available nitrogen or carbon atom in R³ may be substituted by a group R⁴ where R⁴ is an optionally substituted straight or branched chain C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxyl (-OH), amino (-NH₂), 10 -NHR^{1a} [where R^{1a} is an optionally substituted straight or branched chain C₁₋₆ alkyl group], -NR^{1a}R^{1b} [where R^{1b} is as defined for R^{1a} and may be the same as or different to R^{1a}], carboxyl (-CO₂H), esterified carboxyl (-CO₂Alk¹, where Alk¹ is as defined below in connection with the group R⁵), -COR^{1a}, carboxamido (-CONH₂), thiocarboxamido (-CSNH₂), 15 -CONHR^{1a}, -CONR^{1a}R^{1b}, -CSNHR^{1a}, -CSNR^{1a}R^{1b}, -SO₂R^{1a}, -SO₂NH₂, -SO₂NHR^{1a}, -SO₂NR^{1a}R^{1b}, imido, -SC(NH)NH₂, -NHC(NH)NH₂, -NHC(NH)R^{1a} or an optionally substituted aromatic group. Additionally, 20 any available carbon atom in the heterocycloalkyl group represented by R³ may be linked to an oxygen or sulphur atom to form a -C(O)- or -C(S)- group.

The heterocycloalkyl group R³ may contain one, two, three or more R⁴ substituents, the upper limit depending on the size of the ring and number of available carbon and/or nitrogen atoms.

25 When the substituent R⁴ is an optionally substituted alkyl or alkoxy group it may be for example an optionally substituted methyl, ethyl, prop-1-yl, prop-2-yl, methoxy or ethoxy group.

30 The groups R^{1a} and R^{1b} when present in the substituent R⁴ may be for example optionally substituted C₁₋₃ alkyl groups such as optionally substituted methyl or ethyl groups.

35 Optional substituents which may be present on alkyl or alkoxy groups represented by R⁴, or in R^{1a} and/or R^{1b} groups, include one or two substituents selected from C₁₋₆ alkoxy, -OH, -NH₂, -NHR^{1a}, -NR^{1a}R^{1b},

-CO₂H, -CO₂Alk¹, -COR^{1a}, -CONH₂, -CSNH₂, -CONHR^{1a}, -CONR^{1a}R^{1b}, -CSNHR^{1a}, -CSNR^{1a}R^{1b}, -SO₂R^{1a}, -SO₂NH₂, -SO₂NHR^{1a}, -SO₂NR^{1a}R^{1b}, imido, -SC(NH)NH₂, -NHC(NH)NH₂, -NHC(NH)R^{1a} or optionally substituted aromatic groups.

5

Optionally substituted aromatic groups represented by the substituent R⁴ or present as an optional substituent on a group R⁴, R^{1a} or R^{1b} include optionally substituted Ar¹ groups where Ar¹ is as defined herein for the group Ar. The optional substituents which may be present on the group 10 Ar¹ include those -R⁵ or -Alk(R⁵)_m substituents described below in relation to the group Ar.

Particular examples of R³ groups include optionally substituted azetidinyl, 15 pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl or thiomorpholinyl groups. As explained above, these particular heterocycloalkyl groups may be attached to the remainder of the compound of the invention through any of their available ring carbon or nitrogen atoms.

Particular R⁴ substituents which may be present on R³ heterocycloalkyl 20 groups include for example -CH₃, -CH₂CH₃, -(CH₂)₂CH₃, -CH(CH₃)₂, -OH, -OCH₃, -OCH₂CH₃, -O(CH₂)₂NH₂, -O(CH₂)₂NHCH₃, -O(CH₂)₂N(CH₃)₂, -CH₂OH, -(CH₂)₂OH, -(CH₂)₃OH, -CH₂NH₂, -CH₂NHCH₃, -CH₂N(CH₃)₂, -(CH₂)₂NH₂, -(CH₂)₂NHCH₃, 25 -(CH₂)₂N(CH₃)₂, -NH₂, -NHCH₃, -N(CH₃)₂, -SO₂NH₂, -SO₂NHCH₃, -SO₂N(CH₃)₂, -(CH₂)₃-phthalimido, -Ar¹ or -CH₂Ar¹ groups where in each instance Ar¹ is an optionally substituted phenyl group.

Aromatic groups represented by Ar in compounds of formula (1) include 30 for example optionally substituted monocyclic or bicyclic fused ring C₆-12 aromatic groups, such as optionally substituted phenyl, 1- or 2-naphthyl, indanyl or indenyl groups.

Optional substituents which may be present on the aromatic group Ar include one, two, three or more substituents each represented by the atom 35 or group R⁵ or -Alk(R⁵)_m where R⁵ is a halogen atom, or an amino (-NH₂), substituted amino, nitro, cyano, hydroxyl (-OH), substituted hydroxyl,

formyl, carboxyl (-CO₂H), esterified carboxyl, thiol (-SH), substituted thiol, -COR⁶ [where R⁶ is a -Alk(R⁵)_m, aryl or heteroaryl group], -CSR⁶, -SO₃H, -SO₂R⁶, -SO₂NH₂, -SO₂NHR⁶, SO₂N[R⁶]₂, -CONH₂, -CSNH₂, -CONHR⁶, -CSNHR⁶, -CON[R⁶]₂, -CSN[R⁶]₂, -NHSO₂H, -NHSO₂R⁶,
5 -N[SO₂R⁶]₂, -NHSO₂NH₂, -NHSO₂NHR⁶, -NHSO₂N[R⁶]₂, -NHCOR⁶,
-NHCONH₂, -NHCONHR⁶, -NHCON[R⁶]₂, -NHCSR⁶, -NHC(O)OR⁶,
cycloalkyl, heterocycloalkyl, aryl or heteroaryl group; Alk is a straight or
10 branched C₁₋₆ alkylene, C₂₋₆ alkenylene or C₂₋₆ alkynylene chain,
optionally interrupted by one, two or three -O- or -S- atoms or groups
selected from S-(O)-, -S(O)₂- or -N(R⁶)- [where R⁶ is a hydrogen atom or
a straight or branched chain C₁₋₆ alkyl group]; and m is zero or an integer
1, 2 or 3.

When in the group -Alk(R⁵)_m m is an integer 1, 2 or 3, it is to be
15 understood that the substituent or substituents R⁵ may be present on any
suitable carbon atom in -Alk. Where more than one R⁵ substituent is
present these may be the same or different and may be present on the
same or different atom in -Alk or in R⁵ as appropriate. Thus for example,
-Alk(R⁵)_m may represent a -CH(R⁵)₂ group, such as a -CH(OH)Ar² group
20 where Ar² is an aryl or heteroaryl group as defined below. Clearly, when
m is zero and no substituent R⁵ is present the alkylene, alkenylene or
alkynylene chain represented by Alk becomes an alkyl, alkenyl or alkynyl
group.

25 When R⁵ is a substituted amino group it may be for example a group
-NHR⁶ [where R⁶ is as defined above] or a group -N[R⁶]₂ wherein each R⁶
group is the same or different.

When R⁵ is a halogen atom it may be for example a fluorine, chlorine,
30 bromine, or iodine atom.

When R⁵ is a substituted hydroxyl or substituted thiol group it may be for
example a group -OR⁶ or -SR⁶ respectively.

35 Esterified carboxyl groups represented by the group R⁵ include groups of
formula -CO₂Alk¹ wherein Alk¹ is a straight or branched, optionally

substituted C₁-8 alkyl group such as a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl group; a C₆-12arylC₁-8alkyl group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl or 2-naphthylmethyl group; a C₆-12aryl group such as an optionally substituted phenyl, 1-naphthyl or 2-naphthyl group; a C₆-12aryloxyC₁-8alkyl group such as an optionally substituted phenoxyethyl, phenoxyethyl, 1-naphthoxyethyl, or 2-naphthoxyethyl group; an optionally substituted C₁-8alkanoyloxyC₁-8alkyl group, such as a pivaloyloxyethyl, propionyloxyethyl or propionyloxypropyl group; or a C₆-12aroyloxyC₁-8alkyl group such as an optionally substituted benzyloxyethyl or benzyloxypropyl group. Optional substituents present on the Alk¹ group include R⁵ substituents described above.

When Alk is present in or as a substituent, it may be for example a 15 methylene, ethylene, n-propylene, i-propylene, n-butylene, i-butylene, s-butylene, t-butylene, ethylene, 2-propenylene, 2-butenylene, 3-butenylene, ethynylene, 2-propynylene, 2-butynylene or 3-butynylene chain, optionally interrupted by one, two, or three -O- or -S-, atoms or -S(O)-, -S(O)₂- or -N(R⁷)- groups.

20 Cycloalkyl groups represented by the group R⁵ include C₅-7 cycloalkyl groups such as cyclopentyl or cyclohexyl groups.

Heterocycloalkyl groups represented by the group R⁵ include optionally 25 substituted heteroC₃-6cycloalkyl groups containing one or two oxygen, sulphur or nitrogen containing groups as described above in relation to the group R³.

Aryl and heteraryl groups represented by the groups R⁵, R⁶ or Ar² 30 include for example optionally substituted monocyclic or bicyclic C₆-12 aromatic groups such as optionally substituted phenyl, 1- or 2-naphthyl groups, or optionally substituted monocyclic or bicyclic C₁-9 heteroaromatic groups such as optionally substituted pyrrolyl, furyl, thieryl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazole, pyridyl, pyrimidinyl,

pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, 5 quinolizinyl, quinazolinyl, phthalazinyl, quinoxaliny, cinnolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl and 5,6,7,8-tetrahydroisoquinolyl, purinyl, or pteridinyl groups. Optional substituents which may be present on these aromatic and heteroaromatic 10 groups include those optional substituents described above in relation to the group R⁴, but excluding optionally substituted aromatic groups.

Particularly useful atoms or groups represented by R⁵, or Alk(R⁵)_m as appropriate, include fluorine, chlorine, bromine or iodine atoms, or C₁₋₆ 15 alkyl, e.g. methyl or ethyl, C₁₋₆ alkylamino, e.g. methylamino or ethylamino, C₁₋₆hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, C₁₋₆ alkylthiol e.g. methylthiol or ethylthiol, C₁₋₆alkoxy, e.g. methoxy, ethoxy, n-propoxy or n-butoxy, haloC₁₋₆alkoxy, e.g. trifluoromethoxy, C₅₋₇cyclo- 20 alkoxy, e.g. cyclopentyloxy, haloC₁₋₆alkyl, e.g. trifluoromethyl, C₁₋₆alkylamino, e.g. methylamino or ethylamino, amino (-NH₂), aminoC₁₋₆ alkyl, e.g. aminomethyl or aminoethyl, C₁₋₆dialkylamino, e.g. dimethylamino or diethylamino, C₁₋₆dialkylaminoC₁₋₆alkoxy, e.g. dimethylaminoethoxy or diethylaminoethoxy, imido, such as phthalimido or naphthalimido, e.g. 1,8-naphthalimido, 1,1,3-trioxo-benzo[d]thiazolidino, nitro, 25 cyano, hydroxyl (-OH), formyl [HC(O)-], carboxyl (-CO₂H), -CO₂Alk¹ [where Alk¹ is as defined above], C₁₋₆ alkanoyl, e.g. acetyl, thiol (-SH), thioC₁₋₆ alkyl, e.g. thiomethyl or thioethyl, -SC(NH)NH₂, phenoxy, sulphonyl (-SO₃H), C₁₋₆ alkylsulphonyl, e.g. methylsulphonyl, amino- 30 sulphonyl (-SO₂NH₂), C₁₋₆ alkylaminosulphonyl, e.g. methylamino-sulphonyl or ethylaminosulphonyl, C₁₋₆dialkylamino-sulphonyl, e.g. dimethylaminosulphonyl or diethylaminosulphonyl, phenylaminosulphonyl, carboxamido (-CONH₂), C₁₋₆alkylaminocarbonyl, e.g. methylamino-carbonyl or ethylaminocarbonyl, C₁₋₆ dialkylaminocarbonyl, e.g. dimethylaminocarbonyl or diethylaminocarbonyl, sulphonylamino (-NHSO₂H), C₁₋₆ alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, 35 C₁₋₆dialkylsulphonylamino, e.g. dimethylsulphonylamino or diethyl-

sulphonylamino, optionally substituted phenylsulphonylamino, e.g. 2-, 3- or 4- substituted phenylsulphonylamino such as 2-nitrophenylsulphonylamino, aminosulphonylamino (-NHSO₂NH₂), C₁-6alkylaminosulphonylamino, e.g. methylaminosulphonylamino or ethylaminosulphonylamino,

5 C₁-6dialkylaminosulphonyl-amino, e.g. dimethylaminosulphonylamino or diethylaminosulphonylamino, phenylaminosulphonylamino, amino-carbonylamino, C₁-6 alkylaminocarbonylamino e.g. methylamino-carbonylamino or ethylaminocarbonyl-amino, C₁-6dialkylamino-carbonylamino, e.g. dimethylaminocarbonylamino or diethylamino-

10 carbonylamino, phenylaminocarbonylamino, C₁-6alkanoylamino, e.g. acetylamino, C₁-6alkanoylaminoC₁-6alkyl, e.g. acetylamino-methyl, C₁-6 alkoxy carbonylamino, e.g. methoxycarbonylamino, ethoxy-carbonylamino or t-butoxycarbonylamino, or optionally substituted heteroC₃-6cycloalkyl, e.g. piperidinyl, piperazinyl, 3-methyl-1-piperazinyl, homopiperazinyl or

15 morpholinyl groups.

Where desired, two R⁵ or -Alk(R⁵)_m substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C₁-6alkylenedioxy group such as methylenedioxy or ethylenedioxy.

20 It will be appreciated that where two or more R⁵ or -Alk(R⁵)_m substituents are present, these need not necessarily be the same atoms and/or groups.

25 The presence of certain substituents in the compounds of formula (1) may enable salts of the compounds to be formed. Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.

30 Acid addition salts include hydrochlorides, hydrobromides, hydroiodides, alkylsulphonates, e.g. methanesulphonates, ethanesulphonates, or isethionates, arylsulphonates, e.g. p-toluenesulphonates, besylates or napsylates, phosphates, sulphates, hydrogen sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates,

35 succinates, lactates, oxalates, tartrates and benzoates.

Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.


5

Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.

10 It will be appreciated that depending on the nature of the group Ar and the substituents R² and R³, the compounds of formula (1) may exist as geometrical isomers and/or may have one or more chiral centres so that enantiomers or diasteromers may exist. It is to be understood that the invention extends to all such isomers of the compounds of formula (1), and
15 to mixtures thereof, including racemates.


One preferred class of compounds of formula (1) is that wherein the pyrimidine group is attached to the pyridyl group to yield a compound of formula (1a):

20



and the salts, solvates, hydrates and N-oxides thereof.

25 Preferred compounds of this type are those of formula (1b):



and the salts, solvates, hydrates and N-oxides thereof.

5 In the compounds of formulae (1), (1a) or (1b) R² is preferably a hydrogen atom.

In the compounds according to the invention the aromatic group represented by Ar is preferably an optionally substituted phenyl group.

10 The optional substituent(s) may be any of those R⁵ or -Alk(R⁵)_m atoms or groups generally or particularly described above or in the Examples hereinafter. Particularly useful substituents include one, two or three R⁵ or -Alk(R⁵)_m substituents present at any position in the phenyl ring, especially at the 3-, 4- and/or 5- positions relative to the carbon atom attached to the remainder of the compound of the invention.

In one particular preference, R³ in compounds of formulae (1), (1a) or (1b) is a piperazine or homopiperazine group, optionally substituted by one or two R⁴ substituents as described above. Preferably, the R³ piperazine or homopiperazine group is attached to the rest of the molecule of formula (1) through one of its nitrogen atoms. The piperazine or homopiperazine group is preferably disubstituted or is especially a monosubstituted group.

20 When the piperazine or homopiperazine is monosubstituted and is attached to the remainder of the molecule of formula (1) through one of its nitrogen atoms then the substituent (R⁴) is preferably attached to the other free ring nitrogen atom. Especially useful R⁴ substituents are those particularly mentioned above and include for example optionally substituted C₁₋₆alkyl, C₁₋₆ alkoxy, -OH-, -NH₂, -NHCH₃, -N(CH₃)₂, -SO₂NR^{1a}R^{1b}, or optionally substituted phenyl groups especially those

groups of these types specifically described above or in the Examples hereinafter.

Preferred compounds according to the invention include the compounds 5 specifically described in the Examples hereinafter.

Compounds according to the invention are potent and selective inhibitors 10 of the protein tyrosine kinases ZAP-70 and syk, as demonstrated by differential inhibition of ZAP-70 and/or syk and other kinases such as cdc2 kinase, EGFr kinase, p56^{lck} kinase, protein kinase C, csk kinase and p59^{fyn} kinase. The ability of the compounds to act in this way may be simply determined by employing tests such as those described in the Examples hereinafter.

15 The compounds according to the invention are thus of particular use in the prophylaxis and treatment of disease in which inappropriate activation of ZAP-70 or syk plays a role. Such diseases include those in which inappropriate activation of T-cells, B-cells, mast cells or platelets is present 20 or in which eosinophilia is a feature. Examples of these diseases include autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and psoriasis; graft v host disease and other transplantation associated rejection events; and allergic diseases such as asthma, atopic dermatitis, allergic rhinitis and allergic conjunctivitis. The compounds are also of use in the reduction of 25 complications following percutaneous transluminal coronary angioplasty, in the prophylaxis and treatment of thrombosis of the major organs, deep vein thrombosis and peripheral vascular disease.

30 For the prophylaxis or treatment of disease the compounds according to the invention may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents.

Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration, or a form suitable for administration by inhalation or insufflation.

- 5 For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
- 10
- 15
- 20

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

- 25 For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

- 30 The compounds for formula (1) may be formulated for parenteral administration by injection e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoule or multi dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents.
- 35 Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

In addition to the formulations described above, the compounds of formula (1) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular 5 injection.

For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, 10 with the use of suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.


The compositions may, if desired, be presented in a pack or dispenser 15 device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.

The quantity of a compound of the invention required for the prophylaxis or 20 treatment of a particular condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100ng/kg to 100mg/kg e.g. around 0.01mg/kg to 40mg/kg body weight for oral or buccal administration, from around 10ng/kg to 50mg/kg body weight for 25 parenteral administration and around 0.05mg to around 1000mg e.g. around 0.5mg to around 1000mg for nasal administration or administration by inhalation or insufflation.

The compounds of the invention may be prepared by a number of 30 processes as generally described below and more specifically in the Examples hereinafter. In the following process description, the symbols Ar, R², R³, R⁴, Alk, Alk¹, Ar and Ar¹ when used in the text or formulae depicted are to be understood to represent those groups described above in relation to formula (1) unless otherwise indicated. In the reactions 35 described below, it may be necessary to protect reactive functional groups, for example hydroxy, amino, thio or carboxy groups, where these

are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice [see, for example, Green, T. W. in "Protective Groups in Organic Synthesis", John Wiley and Sons, 1991]. In some 5 instances, deprotection may be the final step in the synthesis of a compound of formula (1) and the processes according to the invention described hereinafter are to be understood to extend to such removal of protecting groups.

10 Thus according to a further aspect of the invention, a compound of formula (1) may be prepared by reaction of a guanidine of formula (2):



or a salt thereof
15 with an enaminone of formula (3):



where R^9 and R^{10} , which may be the same or different is each a C_{1-6} alkyl 20 group.

The reaction may be performed in a solvent, for example a protic solvent such as an alcohol, e.g. ethanol, methoxyethanol or propanol, optionally in the presence of a base e.g. an alkali metal base, such as sodium 25 hydroxide or potassium carbonate, at an elevated temperature, e.g. the reflux temperature.

Salts of the compounds of formula (2) include acid salts such as inorganic acid salts e.g. hydrochlorides or nitrates.
30 Intermediate guanidines of formula (2) may be prepared by reaction of the corresponding amine ArNH_2 with cyanamide at an elevated temperature. The reaction may be performed in a solvent such as ethanol at an

elevated temperature, e.g. up to the reflux temperature. Where it is desired to obtain a salt of a guanidine of formula (2), the reaction may be performed in the presence of a concentrated acid, e.g. hydrochloric or nitric acid.


5

The amines ArNH_2 are either known compounds or may be obtained by conventional procedures, for example by hydrogenation of the corresponding nitro derivatives using for example hydrogen in the presence of a metal catalyst in a suitable solvent, for example as more 10 particularly described in the interconversion reactions discussed below. The nitrobenzenes for this particular reaction are either known compounds or may be prepared using similar methods to those used for the preparation of the known compounds.

15 Intermediate enaminones of formula (3) are either known compounds or may be prepared by reaction of an acetyl derivative $\text{R}^3\text{COCH}_2\text{R}^2$ with an acetal $(\text{R}^9)(\text{R}^{10})\text{NCH}(\text{OCH}_3)_2$ at an elevated temperature. The starting materials for this reaction are either known compounds or may be prepared by methods analogous to those used for the preparation of the 20 known compounds.

In another process according to the invention, a compound of formula (1) may be prepared by displacement of a leaving atom or group in a pyrimidine of formula (4):

25



[where L is a leaving atom or group], with an amine ArNH_2 .


30 The reaction may be performed at an elevated temperature, for example the reflux temperature, where necessary in the presence of a solvent, for example an alcohol, such as 2-ethoxyethanol or an aromatic hydrocarbon

such as toluene or mesitylene optionally in the presence of a base for example an amine such as pyridine. Where desired, the reaction may also be performed on an intermediate of formula (4) which is linked, for example via its R³ group, to a solid support, such as a polystyrene resin.


5 After the reaction, the desired compound of formula (1) may be displaced from the support by any convenient method, depending on the original linkage chosen. Particular examples of such solid-phase syntheses are given in the Examples hereinafter.

10 Particular examples of leaving atoms or groups represented by L in compounds of formula (4) include halogen atoms such as a chlorine or bromine atom, and sulphonyloxy groups, for example alkylsulphonyloxy groups such as a methylsulphonyloxy group.

15 Intermediate pyrimidines of formula (4) may be prepared by cross-coupling a pyrimidine of formula (5):



20 [where Hal is a halogen atom]
with a pyridine of formula (6):




25 [where Hal¹ is a halogen atom such as a chlorine atom, and M is a metal atom, such as a zinc atom].

30 The reaction may be carried out in the presence of a metal catalyst, for example a metal complex catalyst such as a palladium complex, e.g. tetrakis(triphenylphosphine)palladium, in a solvent such as an ether, e.g. a

cyclic ether such as tetrahydrofuran, at an elevated temperature, e.g. the reflux temperature.


Intermediates of formula (6) may be prepared by conventional procedures,
5 for example, where M is a zinc atom, by reaction of a halide of formula (7):



[where Hal^2 is for example a bromine atom] with tert-butyllithium at a low
10 temperature e.g. around -100°C followed by reaction with a zinc salt, e.g.
zinc chloride at a low temperature, e.g. around -75°C . Both reactions may
be carried out in a solvent such as an ether, e.g. tetrahydrofuran. Any
reactive groups in R^3 not involved in this or the above-described coupling
reaction may need to be in a protected form, the protecting group being
15 removed prior to, during or subsequent to the displacement reaction
involving the pyrimidines of formula (4).

The halide starting materials of formula (7) may be prepared by
displacement of a leaving group from a pyridine of formula (8):


20



[where L is a leaving group as described above] using a nucleophilic
reagent R^3H . The reaction may be performed as described above in
25 relation to the preparation of compounds of formula (1) from the
intermediate pyrimidines of formula (4).

Intermediates of formulae (5) and (8) are either known compounds or may
be prepared using methods analogous to those used for the preparation of
30 the known compounds.


In another example of a displacement reaction according to the invention a compound of formula (1) wherein R³ is an optionally substituted heterocycloalkyl group containing a ring nitrogen atom attached to the remainder of the molecule of formula (1), may be prepared by reaction of a 5 pyrimidine of formula (9):




[where L is a leaving group as previously described], with a heterocyclic 10 amine R^{3a}NH [where R^{3a}N is an optionally substituted heterocycloalkyl group R³ containing at least one nitrogen atom.]

The reaction may be performed as described above in relation to the preparation of compounds of formula (1) from the intermediate pyrimidines 15 of formula (4). The intermediate amines R^{3a}NH are either known compounds or may be prepared from known compounds for example by the simple interconversion reactions described for the groups Ar and/or R³ in the text or Examples hereinafter.

20 The intermediate pyrimidines of formula (9) may be prepared from the corresponding guanidine of formula (2) and an enaminone of formula (10):



25 using the conditions described above for the reaction of intermediates of formulae (2) and (3). The enaminones of formula (10) may be prepared using an appropriate acetyl derivative of formula (11):



with an acetal ($R^9(R^{10})NCH(OCH_3)_2$ as described previously for the preparation of enaminones of formula (3).

5

Compounds of formula (1) may also be prepared by interconversion of other compounds of formula (1) and it is to be understood that the invention extends to such interconversion processes. Thus, for example, standard substitution approaches employing for example alkylation, 10 arylation, heteroarylation, acylation, thioacylation, sulphonylation, formylation or coupling reactions may be used to add new substituents to and/or extend existing substituents in compounds of formula (1). Alternatively existing substituents in compounds of formula (1) may be modified by for example oxidation, reduction or cleavage reactions to yield 15 other compounds of formula (1).

The following describes in general terms a number of approaches which can be employed to modify existing Ar and/or R^3 groups in compounds of formula (1). It will be appreciated that each of these reactions will only be 20 possible where an appropriate functional group exists in a compound of formula (1).

Thus, for example alkylation, arylation or heteroarylation of a compound of formula (1) may be achieved by reaction of the compound with a reagent 25 R^4L , $AlkL$, Ar^1L or Ar^2L where L is a leaving atom or group as described above. The reaction may be carried out in the presence of a base, e.g. an inorganic base such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. potassium t-butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide 30 such as dimethylformamide or an ether, e.g. a cyclic ether such as tetrahydrofuran, at around $0^\circ C$ to around $40^\circ C$.

In a variation of this process the leaving group L may be alternatively part of the compound of formula (1) and the reaction performed with an appropriate nucleophilic reagent at an elevated temperature. Where appropriate the reaction may be performed in a solvent such as an 5 alcohol, e.g. ethanol.

In another general example of an interconversion process, a compound of formula (1) may be acylated or thioacylated. The reaction may be performed for example with an acyl halide or anhydride in the presence of 10 a base, such as a tertiary amine e.g. triethylamine in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane at for example ambient temperature, or by reaction with a thioester in an inert solvent such as tetrahydrofuran at a low temperature such as around 0°C. The reaction is particularly suitable for use with compounds of formula (1) containing 15 primary or secondary amino groups.

In a further general example of an interconversion process, a compound of formula (1) may be formylated, for example by reaction of the compound with a mixed anhydride HCOOCOCH_3 or with a mixture of formic acid and 20 acetic anhydride.

Compounds of formula (1) may be prepared in another general interconversion reaction by sulphonylation, for example by reaction of a compound of formula (1) with a reagent $\text{AlkS(O)}_2\text{L}$, or $\text{Ar}^1\text{S(O)}_2\text{L}$ in the 25 presence of a base, for example an inorganic base such as sodium hydride in a solvent such as an amide, e.g. a substituted amide such as dimethylformamide at for example ambient temperature. The reaction may in particular be performed with compounds of formula (1) possessing a primary or secondary amino group.

30 In another example, a compound of formula (1) may be prepared by sulphonamoylation, for example by reaction of a compound of formula (1) where, for example R^3 contains an available nitrogen atom, with a reagent $\text{R}^{1a}\text{R}^{1b}\text{NSO}_2\text{L}$ in the presence of a solvent, e.g. an organic amine such as 35 triethylamine at around ambient temperature.

In further examples of interconversion reactions according to the invention compounds of formula (1) may be prepared from other compounds of formula (1) by modification of existing functional groups in the latter.

- 5 Thus in one example, ester groups $-\text{CO}_2\text{Alk}^1$ in compounds of formula (1) may be converted to the corresponding acid $[-\text{CO}_2\text{H}]$ by acid- or base-catalysed hydrolysis or by catalytic hydrogenation depending on the nature of the group Alk^1 . Acid- or base-catalysed hydrolysis may be achieved for example by treatment with an organic or inorganic acid, e.g. trifluoroacetic acid in an aqueous solvent or a mineral acid such as hydrochloric acid in a solvent such as dioxan or an alkali metal hydroxide, e.g. lithium hydroxide in an aqueous alcohol, e.g. aqueous methanol. Catalytic hydrogenation may be carried out using for example hydrogen in the presence of a metal catalyst, for example palladium on a support such as carbon in a solvent such as an ether, e.g. tetrahydrofuran or an alcohol, e.g. methanol.
- 10
- 15

In a second example, $-\text{OAlk}^2$ [where Alk^2 represents an alkyl group such as a methyl group] groups in compounds of formula (1) may be cleaved to the corresponding alcohol $-\text{OH}$ by reaction with boron tribromide in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane at a low temperature, e.g. around -78°C .

- 20

In another example, alcohol $-\text{OH}$ groups in compounds of formula (1) may be converted to a corresponding $-\text{OAlk}$ or $-\text{OAr}$ group by coupling with a reagent AlkOH or ArOH in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine and an activator such as diethyl-, diisopropyl-, or dimethylazodicarboxylate.

- 25
- 30 Aminosulphonylamino $[-\text{NHSO}_2\text{NH}_2]$ groups in compounds of formula (1) may be obtained, in another example, by reaction of a corresponding amine $[-\text{NH}_2]$ with sulphanide in the presence of an organic base such as pyridine at an elevated temperature, e.g. the reflux temperature.
- 35 In a further example, amine $[-\text{NH}_2]$ groups in compounds of formula (1) may be obtained by hydrolysis from a corresponding imide by reaction

with hydrazine in a solvent such as an alcohol, e.g. ethanol at ambient temperature.

5 In another example, a nitro [-NO₂] group may be reduced to an amine [-NH₂], for example by catalytic hydrogenation as just described, or by chemical reduction using for example a metal, e.g. tin or iron, in the presence of an acid such as hydrochloric acid.

10 N-oxides of compounds of formula (1) may be prepared for example by oxidation of the corresponding nitrogen base using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for example around 70°C to 80°C, or alternatively by reaction with a peracid such as peracetic acid in a solvent, e.g. dichloromethane, at ambient temperature.

15 Where salts of compounds of formula (1) are desired, these may be prepared by conventional means, for example by reaction of a compound of formula (1) with an appropriate acid or base in a suitable solvent or mixture of solvents, e.g. an organic solvent such as an ether, e.g. diethylether, or an alcohol, e.g. ethanol.

The following Examples illustrated the invention. In the Examples all ¹Hnmr were run at 300MHz unless specified otherwise. All temperatures are in °C. The following abbreviations are used:

25 DMSO - dimethylsulphoxide; DMF - dimethylformamide; THF - tetrahydrofuran.

Intermediates used in the Examples are:

30 **Intermediate 1:** 4-(2-chloropyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine.

Intermediate 2: 1-(2-chloropyridin-5-yl)-3-dimethylamino-2-propen-1-one.

35 The preparations of both **Intermediates** are described in Example 1.

EXAMPLE 1

4-(2-(Piperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine

A mixture of **Intermediate 1** (300mg, 0.81mmol) and piperazine (142mg, 1.65mmol) was heated as a melt at 140° for 1.5h. On cooling to room 5 temperature the mixture was partitioned between dichloromethane and water, dried (MgSO₄) and concentrated under reduced pressure. The residue was subjected to column chromatography [silica methanol-dichloromethane-25% aq.ammonia 10:90:1] to afford the **title compound** (275mg), after trituration with ether, as an off-white solid m.p. 134-135°. 10 δ H (d⁶DMSO) 9.39 (1H, s), 8.92 (1H, d, \downarrow 2.0Hz), 8.42 (1H, d, \downarrow 5.0Hz), 8.24 (1H, d, \downarrow 8.0Hz), 7.28-7.25 (3H, m), 6.90 (1H, d, \downarrow 8.0Hz), 3.78 (6H, s), 3.64 (3H, s), 3.59-3.54 (4H, m), 2.81-2.75 (4H, m) and 2.38 (1H, br s).

Intermediate 1 was prepared by heating a solution of 3,4,5-trimethoxy-15 phenylguanidine (6.42g, 22.3mmol), **Intermediate 2** (4.70g, 22.33mmol) and powdered sodium hydroxide in propan-2-ol at reflux for 3.5h. The solvent was removed under reduced pressure and the residue subjected to column chromatography [silica, 25% hexane-ethyl acetate] to afford the desired product (1.43g) as a yellow solid m.p. 191-192°. δ H (d⁶DMSO) 20 9.63 (1H, s), 9.17 (1H, d, \downarrow 2.0Hz), 8.60 (1H, d, \downarrow 5.1Hz), 8.55 (1H, dd, \downarrow 8.4, 2.5Hz), 7.71 (1H, d, \downarrow 8.4Hz), 7.48 (1H, d, \downarrow 5.1Hz), 7.24 (2H, s), 3.77 (6H, s) and 3.62 (3H, s).

Intermediate 2 was prepared by heating a solution of 5-acetyl-2-chloropyridine (4.50g 28.9mmol) in dimethylformamide diethylacetal (15ml) under reflux for 1h. On cooling the resulting solid was collected by filtration and washed with ether and hexane to give the enaminone (5.07g) as an orange solid m.p. 130-132°. δ H (d⁶DMSO) 8.87 (1H, d, \downarrow 2.0Hz), 8.25 (1H, dd, \downarrow 8.3, 5.2Hz), 7.76 (1H, d, \downarrow 12.2Hz), 7.55 (1H, dd, \downarrow 8.3, 0.6Hz), 5.84 (1H, d, \downarrow 12.2Hz), 3.15 (3H, br s) and 2.93 (3H, br s).

5-Acetyl-2-chloropyridine was prepared by the addition of dimethyl malonate (17.2ml, 150mmol) to a suspension of magnesium chloride (anhydrous) in toluene (200ml) and triethylamine (39.5ml) at room 35 temperature. After the suspension had been stirred for 1.5h, 6-chloronicotinyl chloride in toluene (200ml) was added dropwise over

20min, after which the mixture was stirred for an additional 1.5h. After slow addition of concentrated hydrochloric acid (37ml), the toluene layer was decanted, dried (MgSO_4) and concentrated under reduced pressure. The residue was dissolved in anhydrous DMSO (50ml), heated to 150°, 5 water (3.5ml) added dropwise and heating continued for 1h. Water (400ml) was added, and the resulting solution extracted with diethyl ether (300ml). The ether layer was washed with water (150ml) dried (MgSO_4) and concentrated under reduced pressure to give the desired product (16.0g) as a pale yellow solid m.p. 103°. δH (CDCl_3) 8.90 (1H, d, J 2.8Hz), 8.18 (1H, dd, J 10.0, 4.8Hz), 7.42 (1H, d, J 10.0Hz) and 2.61 (3H, s). 10 15

The following compounds of Examples 2-26 were prepared in a similar manner to the compound of formula (1) using Intermediate 1 as one starting material.

EXAMPLE 2

4-(2-(1,4-Diazacycloheptan-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine

20 From Intermediate 1 (300mg, 0.81mmol) and homopiperazine (600mg, 6mmol) to give the title compound (310mg) as a yellow solid m.p.144-145°. δH (d^6DMSO) 9.35 (1H, s), 8.88 (1H, d, J 2.3Hz), 8.38 (1H, d, J 5.2Hz), 8.22 (1H, dd, J 9.0, 2.4Hz), 7.26-7.24 (3H, m), 6.74 (1H, d, J 9.0Hz), 3.77 (6H, s), 3.76-3.64 (4H, m), 3.62 (3H, s), 2.86-2.83 (2H, m), 25 2.67-2.63 (2H, m) and 1.77-1.73 (2H, m).

EXAMPLE 3

4-(2-(4-Methylpiperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine

30 From Intermediate 1 (200mg, 0.54mmol) and 1-methylpiperazine (400mg, 4mmol) to give the title compound (210mg) as an off-white solid 178-179°. δH (d^6DMSO) 9.39 (1H, s), 8.91 (1H, d, J 2.3Hz), 8.41 (1H, d, J 5.3Hz), 8.26 (1H, dd, J 9.0, 2.3Hz), 7.29-7.25 (3H, m), 6.94 (1H, d, J 9.1Hz), 3.77 (6H, s), 3.62-3.60 (7H, m), 2.40-2.37 (4H, m) and 2.20 (3H, s).

EXAMPLE 4**4-(2-(3-(R,S)-Methylpiperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxy-phenyl)-2-pyrimidineamine**

From Intermediate 1 (700mg, 1.89mmol) and 2(R,S)-methylpiperazine (1.0g, 10mmol) to give the title compound (300mg) as a pale yellow solid m.p. 138-139°. δ H (CDCl₃) 8.87 (1H, d, \downarrow 2.1Hz), 8.37 (1H, d, \downarrow 5.3Hz), 8.21 (1H, dd, \downarrow 9.0, 2.5Hz), 7.21 (1H, s), 7.03 (1H, d, \downarrow 5.3Hz), 7.01 (2H, s), 6.67 (1H, d, \downarrow 9.0Hz), 4.33-4.13 (2H, m), 3.89 (6H, s), 3.83 (3H, s), 3.16-3.13 (1H, m), 3.03-2.88 (3H, m), 2.65-2.57 (1H, m), 1.98 (1H, br s) and 1.18 (3H, d, \downarrow 6.2Hz).

EXAMPLE 5**4-(2-(3(S)-Methylpiperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxy-phenyl)-2-pyrimidineamine**

From Intermediate 1 (740mg, 2.0mmol) and 2(S)-methylpiperazine (7.50mg, 7.5mmol) to give the title compound (670mg) as a yellow solid m.p. 139-140°. δ H (CDCl₃) 8.87 (1H, d, \downarrow 2.2Hz), 8.37 (1H, d, \downarrow 5.3Hz), 8.21 (1H, dd, \downarrow 9.0, 2.4Hz), 7.33 (1H, s), 7.03 (1H, d, \downarrow 5.3Hz), 7.01 (2H, s), 6.66 (1H, d, \downarrow 9.0Hz), 4.32-4.24 (2H, m), 3.89(6H, s), 3.83 (3H, s), 3.16-3.13 (1H, m), 3.03-2.89 (3H, m), 2.65-2.57 (1H, m), 2.19 (1H, br s) and 1.18 (3H, d, \downarrow 6.2Hz).

EXAMPLE 6**4-(2-(3(R)-Methylpiperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxy-phenyl)-2-pyrimidineamine**

From Intermediate 1 (740mg, 2.0mmol) and 2(R)-methylpiperazine (750mg, 7.5mmol) to give the title compound (560mg) as a yellow solid m.p. 138-139°. δ H (CDCl₃) 8.87 (1H, d, \downarrow 2.2Hz), 8.37 (1H, d, \downarrow 5.3Hz), 8.20 (1H, dd, \downarrow 9.0, 2.4Hz), 7.33 (1H, s), 7.03 (1H, d, \downarrow 5.3Hz), 7.01 (2H, s), 6.67 (1H, d, \downarrow 9.0Hz), 4.32-4.24 (2H, m), 3.89 (6H, s), 3.03 (3H, s), 3.16-3.13 (1H, m), 3.03-2.89 (3H, m), 2.65-2.57 (1H, m) and 1.18 (3H, d, \downarrow 6.2Hz).

EXAMPLE 7**4-(2-(4-Ethylpiperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine**

From Intermediate 1 (350mg, 0.945mmol) and 1-ethylpiperazine (457mg, 5 mmol) to give the title compound (400mg) as an off-white solid m.p. 139-139°. δ H (CDCl₃) 8.87 (1H, d, J 2.0Hz), 8.37 (1H, d, J 5.3Hz), 8.21 (1H, dd, J 9.0, 2.5Hz), 7.18 (1H, s), 7.04 (1H, d, J 5.3Hz), 7.01 (2H, s), 6.68 (1H, d, J 9.0Hz), 3.90 (6H, s), 3.84 (3H, s), 3.70 (4H, m), 2.57 (4H, m), 2.48 (2H, q, J 7.2Hz) and 1.14 (3H, t, J 7.2).

10

EXAMPLE 8**4-(2-(3,5-Dimethylpiperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine**

15 From Intermediate 1 (350mg, 0.85mmol) and 2,6-dimethylpiperazine (500mg, 4.4mmol) to give the title compound (180mg) as a yellow solid m.p. 110-111°. δ H (CDCl₃) 8.86 (1H, d, J 2.0Hz), 8.36 (1H, d, J 5.3Hz), 8.21 (1H, dd, J 9.0, 2.5Hz), 7.20 (1H, br s), 7.03 (1H, d, J 5.3Hz), 7.01 (2H, s), 6.68 (1H, d, J 9.0Hz), 4.28 (2H, dd, J 2.8, 2.3Hz), 3.90 (6H, s), 20 3.84 (3H, s), 2.98-2.92 (2H, m), 2.50 (2H, dd, J 12.6, 10.6Hz), 1.69 (1H, br s) and 1.17 (6H, d, J 6.3Hz).

EXAMPLE 9**4-(2-(3-Hydroxymethylpiperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine**

From Intermediate 1 (740mg, 2mmol) and 3-piperazinemethanol (800mg, 6.89mmol) to give the title compound (580mg) as a yellow solid m.p. 118-119°. δ H (CDCl₃) 8.86 (1H, d, J 2.2Hz), 8.37 (1H, d, J 5.3Hz), 8.20 (1H, dd, J 9.0, 2.5Hz), 7.27 (1H, s), 7.03 (1H, d, J 5.3Hz), 7.01 (2H, s), 6.68 (1H, d, J 9.0Hz), 4.25-4.18 (2H, m), 3.89 (6H, s), 3.84 (3H, s), 3.75 (1H, dd, J 10.8, 4.1Hz), 3.62 (1H, dd, J 10.8, 6.3Hz), 3.20-2.91 (5H, m) and 2.13 (2H, br s).

35

EXAMPLE 10**4-(2-(3-N,N-Dimethylaminomethyl)piperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine**

From Intermediate 1 (400mg, 1.08mmol) and 2-dimethylaminomethyl-5 piperazine (500mg, 3.5mmol) to give the title compound (360mg) as a yellow solid m.p. 86-87°. δ H (CDCl₃) 8.87 (1H, d, \downarrow 2.2Hz), 8.36 (1H, d, \downarrow 5.3Hz), 8.20 (1H, dd, \downarrow 9.0, 2.2Hz), 7.27 (1H, s), 7.03 (1H, d, \downarrow 5.3Hz), 7.01 (2H, s), 6.68 (1H, d, \downarrow 9.0Hz), 4.25 (2H, 6t, \downarrow 13Hz), 3.89 (6H, s), 3.83 (3H, s), 3.16-3.02 (2H, m), 2.93-2.83 (2H, m), 2.64 (1H, dd, \downarrow 12.3, 10.2Hz), 2.40 (1H, dd, \downarrow 12.1, 9.7Hz), 2.26 (6H, s), 2.23-2.21 (1H, m) and 2.12 (1H, s).

EXAMPLE 11**4-(2-(3(R)-(Prop-2-yl)piperazin-1-yl)pyridine-5-yl)-N-(3,4,5-trimethoxy-phenyl)-2-pyrimidineamine**

From Intermediate 1 (555mg, 1.5mmol) and 2(R)-(prop-2-yl)piperazine (641mg, 5mmol) to give the title compound (280mg) as a yellow solid m.p. 91° (decomp). δ H (CDCl₃) 8.89 (1H, d, \downarrow 2.4Hz), 8.37 (1H, d, \downarrow 5.3Hz), 8.21 (1H, dd, \downarrow 9.0, 2.4Hz), 7.18 (1H, s), 7.04 (1H, d, \downarrow 5.3Hz), 7.02 (2H, s), 6.67 (1H, d, \downarrow 9.0Hz), 4.38 (1H, bd, \downarrow 12.5Hz), 4.24 (1H, bd, \downarrow 12.5Hz), 3.90 (6H, s), 3.84 (3H, s), 3.18 (1H, m), 2.99-2.88 (2H, m), 2.74-2.66 (1H, m), 2.51-2.48 (1H, m), 1.76 (1H, br s), 1.72-1.69 (1H, m), 1.04 (3H, d, \downarrow 6.7Hz) and 1.02 (3H, d, \downarrow 6.7Hz).

25

EXAMPLE 12**4-(2-(4-(4-Nitrophenyl)piperazin-1-yl)pyridin-5-yl)N-(3,4,5-trimethoxy-phenyl)-2-pyrimidineamine**

From Intermediate 1 (350mg, 0.95mmol) and 1-(4-nitrophenyl)piperazine (415mg, 2mmol) to give the title compound (220 mg) as a yellow solid m.p. 222-223°. δ H (CDCl₃) 8.92 (1H, s), 8.39 (1H, d, \downarrow 5.3Hz), 8.26 (1H, d, \downarrow 9.0Hz), 8.17 (2H, d, \downarrow 9.3Hz), 7.11 (1H, s), 7.06 (1H, d, \downarrow 5.3Hz), 7.02 (2H, s), 6.85 (2H, d, \downarrow 9.3Hz), 6.71 (1H, d, \downarrow 9.0Hz), 3.91-3.89 (10H, m), 3.84 (3H, s) and 3.65-3.61 (4H, m).

35

EXAMPLE 13**4-(2-(4-(3-Hydroxypropyl)piperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine**

From Intermediate 1 (700mg, 1.89mmol) and 1-(3-hydroxypropyl)-5 piperazine (1.09g, 7mmol) to give the title compound (750mg) as a yellow solid m.p.116-117°. δ H (CDCl₃) 8.88 (1H, d, \downarrow 2.2Hz), 8.37 (1H, d, \downarrow 5.3Hz), 8.21 (1H, dd, \downarrow 9.0, 2.5Hz), 7.20 (1H, s), 7.03 (1H, d, \downarrow 5.3Hz), 7.01 (2H, s), 6.67 (1H, d, \downarrow 9.0Hz), 3.89 (6H, s), 3.86-3.80 (4H, m), 3.83 (3H, s), 3.70-3.67 (4H, m), 2.69-2.63 (4H, m) and 1.80-1.78 (2H, m).

10

EXAMPLE 14**4-(2-(3-(2-Hydroxyethyl)piperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine**

From Intermediate 1 (740mg, 2mmol) and 2-(2-hydroxyethyl)piperazine (800mg, 6.15mmol) to give the title compound (450mg) as a yellow solid m.p. 150-151°. δ H (CDCl₃) 8.86 (1H, d, \downarrow 2.3Hz), 8.37 (1H, d, \downarrow 5.2Hz), 8.21 (1H, dd, \downarrow 9.0, 2.4Hz), 7.18 (1H, s), 7.03 (1H, d, \downarrow 5.3Hz), 7.01 (2H, s), 6.68 (1H, d, \downarrow 9.0Hz), 4.40-4.22 (2H, m), 3.90-3.85 (2H, m), 3.89 (6H, s), 3.25-3.09 (4H, m), 2.98-2.92 (3H, m) and 1.89-1.83 (2H, m).

20

EXAMPLE 15**4-(2-(4-(2-Aminoethyl)piperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxy-phenyl)-2-pyrimidineamine**

From Intermediate 1 (750mg, 2.02 mmol) and 1-(2-aminoethyl)-25 piperazine (1.04g, 8mmol) to give the title compound (405mg) as a white solid m.p. 88-89°. δ H (CDCl₃) 8.87 (1H, d, \downarrow 2.1Hz), 8.37 (1H, d, \downarrow 5.4Hz), 8.21 (1H, dd, \downarrow 9.0, 3.4Hz), 7.12 (1H, s), 7.05-7.02 (3H, m), 6.67 (1H, d, \downarrow 9.0Hz), 3.90 (6H, s), 3.84 (3H, s), 3.71-3.67 (4H, m), 2.85 (2H, t, \downarrow 5.0Hz), 2.60-2.56 (4H,m) and 2.49 (2H, t, \downarrow 6.0Hz).

30

EXAMPLE 16**4-(2-(4-(2-Hydroxyethyl)piperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine**

From Intermediate 1 (300mg, 0.81mmol) and 1-(2-hydroxyethyl)-35 piperazine (524mg, 4.0mmol) to give the title compound (263mg) as an off-white solid m.p. 156-157°. δ H (CDCl₃) 8.88 (1H, d, \downarrow 2.3Hz), 8.37

(1H, d, \downarrow 5.3Hz), 8.21 (1H, dd, \downarrow 9.0, 2.5Hz), 7.13 (1H, s), 7.03 (3H, m), 6.68 (1H, d, \downarrow 8.9Hz), 3.90 (6H, s), 3.83 (3H, s), 3.69 (6H, m) and 2.63 (6H, m).

5 **EXAMPLE 17**

4-(2-(N-Morpholino)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine

From **Intermediate 1** (200mg, 0.54mmol), and morpholine (0.75ml, 8.61mmol) to give the **title compound** (160mg) as a buff solid m.p. 157-10 158°. δ H (CDCl₃) 9.40 (1H, s), 8.94 (1H, s), 8.42 (1H, d, \downarrow 5.1Hz), 8.30 (1H, d, \downarrow 8.8Hz), 7.37 (1H, d, \downarrow 5.1Hz), 7.26 (2H, s), 6.95 (1H, d, \downarrow 8.8Hz), 3.77 (6H, s), 3.70-3.67 (4H, m), 3.61 (3H, s) and 3.58-2.54 (4H, m).

EXAMPLE 18

15 **4-(2-(N-Thiomorpholino)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine**

From **Intermediate 1** (350mg, 0.95mmol) and thiomorpholine (413mg, 4mmol) to give the **title compound** (353mg) as a buff solid m.p. 177-178°. δ H (CDCl₃) 8.87 (1H, d, \downarrow 2.2Hz), 8.38 (1H, d, \downarrow 5.3Hz), 8.20 (1H, dd, \downarrow 9.0, 2.3Hz), 7.21 (1H, s), 7.05-7.01 (3H, m), 6.67 (1H, d, \downarrow 9.0Hz), 4.08-20 4.04 (4H, m), 3.90 (6H, s), 3.84 (3H, s) and 2.71-2.67 (4H, m).

EXAMPLE 19

25 **4-(2-(Piperid-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine**

From **Intermediate 1** (700mg, 1.89mmol) and piperidine (0.93ml, 9.45mmol) to give the **title compound** (213mg) as a buff solid m.p. 150°. δ H (CDCl₃) 8.86 (1H, d, \downarrow 2.5Hz), 8.35 (1H, d, \downarrow 5.3Hz), 8.18 (1H, dd, \downarrow 9.1, 2.5Hz), 7.14 (1H, br s), 7.03 (1H, d, \downarrow 5.3Hz), 7.01 (2H, s), 6.67 (1H, d, \downarrow 9.1Hz), 3.90 (6H, s), 3.84 (3H, s), 3.67-3.66 (4H, m) and 1.68 (6H, m).

EXAMPLE 20

4-(2-(2-Hydroxymethylpiperid-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine

35 From **Intermediate 1** (300mg, 0.8mmol) and 2-(hydroxymethyl)piperidine (2.0g, 17.4mmol) to give the **title compound** (43mg) as a yellow solid m.p.

93°. δ H (CDCl₃) 8.78 (1H, d, \downarrow 2.0Hz), 8.34 (1H, d, \downarrow 5.3Hz), 8.14 (1H, dd, \downarrow 9.1, 2.3Hz), 7.54 (1H, s), 7.00 (2H, s), 6.98 (1H, d, \downarrow 5.4Hz), 6.71 (1H, d, \downarrow 9.1Hz), 4.78 (1H, m), 4.04 (2H, m), 3.87 (6H, s), 3.83 (3H, s), 3.74 (2H, m), 3.17 (1H, m) and 1.71 (6H, m).

5

EXAMPLE 21

4-(2-(3-Hydroxymethylpiperid-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine

From Intermediate 1 (750mg, 2.02mmol) and 3-(hydroxymethyl)piperidine (9.22mg, 8.0mmol) to give the title compound (825 mg) as a pale yellow solid m.p. 183-184°. δ H (CDCl₃) 8.83 (1H, d, \downarrow 2.3Hz), 8.35 (1H, d, \downarrow 5.3Hz), 8.17 (1H, dd, \downarrow 9.0, 2.4Hz), 7.20 (1H, s), 7.02 (3H, m), 6.70 (1H, d, \downarrow 9.0Hz), 3.90 (6H, s), 3.87-3.80 (2H, m), 3.84 (3H, s), 3.79-3.64 (1H, m), 3.55-3.41 (3H, m), 2.98 (1H, br s), 1.91-1.84 (1H, m), 1.73-1.69 (2H,m) and 1.60-1.46 (2H,m).

10

EXAMPLE 22

4-(2-(4-Hydroxypiperid-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine

20 From Intermediate 1 (500mg, 1.35mmol) and 4-hydroxypiperidine (556mg, 5.5mmol) to give the title compound (507mg) as a yellow solid m.p. 127-128°. δ H (CDCl₃) 8.86 (1H, d, \downarrow 2.3Hz), 8.36 (1H, d, \downarrow 5.3Hz), 8.19 (1H, dd, \downarrow 9.0, 3.4Hz), 7.29 (1H, s), 7.04-7.00 (3H, m), 6.69 (1H, d, \downarrow 9.0Hz), 4.18-4.13 (2H, m), 3.98-3.88 (1H, m), 3.89 (6H, s), 3.83 (3H, s), 25 3.34-3.27 (2H, m), 2.05-1.95 (2H, m), 1.76 (1H, br s) and 1.61-1.52 (2H, m).

15

EXAMPLE 23

4-(2-(3-(R)-Dimethylaminopyrrolidin-1-yl)pyridin-5-yl)-N-(3,4,5-

30 trimethoxyphenyl)-2-pyrimidineamine

From Intermediate 1 (350mg, 0.95mmol) and 3(R)-dimethylamino-pyrrolidine (540mg, 4.73mmol) to give the title compound (220mg) as a yellow solid m.p. 150-151°. δ H (CDCl₃) 8.86 (1H, d, \downarrow 2.0Hz), 8.35 (1H, d, \downarrow 5.3Hz), 8.21 (1H, dd, \downarrow 8.8, 2.3Hz), 7.17 (1H, s), 7.04-7.00 (3H, m), 35 6.41 (1H, d, \downarrow 8.8Hz), 3.89 (6H, s), 3.83 (3H, s), 3.74 (1H, t, \downarrow 8.0Hz),

3.65-3.47 (1H, m), 3.43-3.30 (1H, m), 2.89-2.83 (1H, m), 2.34 (6H, s), 2.29-2.25 (1H, m) and 2.04-1.93 (2H, m).

EXAMPLE 24

5 **4-(2-(3(S)-Dimethylaminopyrrolidin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine**
 From Intermediate 1 (350mg, 0.95mmol) and (S)-3-dimethylamino-pyrrolidine (540mg, 4.73mmol) to give the title compound as a yellow solid m.p. 149-150°. δ H (CDCl₃) 8.86 (1H, d, \downarrow 2.0Hz), 8.35 (1H, d, \downarrow 5.3Hz), 8.21 (1H, dd, \downarrow 8.8, 2.3Hz), 7.17 (1H, s), 7.04-7.00 (3H, m), 6.41 (1H, d, \downarrow 8.8Hz), 3.89 (6H, s), 3.83 (3H, s), 3.74 (1H, t, \downarrow 8.0Hz), 3.65-3.47 (1H, m), 3.43-3.30 (1H, m), 2.89-2.83 (1H, m), 2.34 (6H, s), 2.29-2.25 (1H, m) and 2.04-1.93 (2H, m).

15 **EXAMPLE 25**

4-(2-(3-Hydroxyazetidin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine

From Intermediate 1 (370mg, 1.0mmol) and 3-hydroxyazetidine (350mg,

3.2mmol) to give the title compound (115mg) as a yellow solid m.p. 186-

20 187°. δ H (CDCl₃) 8.81 (1H, d, \downarrow 2.3Hz), 8.36 (1H, d, \downarrow 5.3Hz), 8.16 (1H, dd, \downarrow 8.7, 2.3Hz), 7.34 (1H, br s), 7.00 (1H, d, \downarrow 5.3Hz), 6.97 (2H, s), 6.29 (1H, d, \downarrow 8.7Hz), 4.85-4.80 (1H, m), 4.40-4.35 (2H, m), 3.98-3.93 (2H, m), 3.88 (6H, s) and 3.83 (3H, s).

25 **EXAMPLE 26**

4-(2-(4-Methyl-1,4-diazacycloheptan-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine

From Intermediate 1 (500 mg, 1.34mmol) and 1-methylhomopiperazine

(1.67ml, 13.4mmol) to give the title compound (92mg) as a buff solid m.p.

30 141°. δ H (CDCl₃) 8.86 (1H, d, \downarrow 2.1Hz), 8.35 (1H, d, \downarrow 5.3Hz), 8.19 (1H, dd, \downarrow 9.1, 2.4Hz), 7.09 (1H, br s), 7.03 (1H, d, \downarrow 5.3Hz), 7.02 (2H, s), 6.54 (1H, d, \downarrow 9.1Hz), 3.91 (8H, br s), 3.84 (3H, s), 3.72 (2H, t, \downarrow 6.2Hz), 2.74 (2H, t, \downarrow 4.9Hz), 2.60 (2H, t, \downarrow 5.3Hz), 2.39 (3H, s) and 2.04 (2H, m).

EXAMPLE 27**4-(2-(3(S),4-Dimethylpiperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxy-phenyl)-2-pyrimidineamine**

To a suspension of potassium carbonate (70mg, 0.5mmol) in dry tetrahydrofuran (15ml) under a nitrogen atmosphere was added the compound of Example 5 (180mg, 0.41mmol) followed by iodomethane (0.028ml, 0.45mmol) and the mixture stirred at room temperature for 2h. After this time the solvent was removed under reduced pressure and the residue subjected to column chromatography [SiO₂; 7% methanol-dichloromethane] to give the title compound (120mg) as a pale yellow solid m.p. 92-93°. δ H (CDCl₃) 8.87 (1H, d, \downarrow 2.4Hz), 8.36 (1H, d, \downarrow 5.3Hz), 8.21 (1H, dd, \downarrow 9.0, 2.5Hz), 7.14 (1H, s), 7.03 (1H, d, \downarrow 5.3Hz), 7.01 (2H, s), 6.68 (1H, d, \downarrow 9.0Hz), 4.24-4.17 (2H, m), 3.90 (6H, s), 3.84 (3H, s), 3.21-3.12 (1H, m), 2.93-2.88 (1H, m), 2.76 (1H, dd, \downarrow 13.1, 10.2Hz), 2.34 (3H, s), 2.33-2.29 (1H, m), 2.20-2.10 (1H, m) and 1.17 (3H, d, \downarrow 6.2Hz).

The following compound was prepared in a similar manner:

EXAMPLE 28**4-(2-(3(R),4-Dimethylpiperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxy-phenyl)-2-pyrimidineamine**

From the compound of Example 6 (180mg, 0.41mmol), iodomethane (0.028ml, 0.45mmol) and potassium carbonate (70mg, 0.5mmol) to give the title compound (150mg) as a pale yellow solid m.p. 92-93°. δ H (CDCl₃) 8.87 (1H, d, \downarrow 2.4Hz), 8.36 (1H, d, \downarrow 5.3Hz), 8.21 (1H, dd, \downarrow 9.0, 2.5Hz), 7.14 (1H, s), 7.03 (1H, d, \downarrow 5.3Hz), 7.01 (2H, s), 6.68 (1H, d, \downarrow 9.0Hz), 4.24-4.17 (2H, m), 3.90 (6H, s), 3.84 (3H, s), 3.21-3.12 (1H, m), 2.93-2.88 (1H, m), 2.76 (1H, dd, \downarrow 13.1, 10.2Hz), 2.34 (3H, s), 2.33-2.29 (1H, m), 2.20-2.10 (1H, m), and 1.17 (3H, d, \downarrow 6.2Hz).

EXAMPLE 29**4-(2-(4-(3-Phthalimidopropyl)piperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine**

To a suspension of caesium carbonate (245mg, 0.75mmol) in DMF (20ml) was added the compound of Example 1 (300mg, 0.71mmol) and 3-bromopropylphthalimide (191mg, 0.71mmol) and the mixture stirred at room temperature for 4h. The solvent was removed under reduced

pressure and the residue subjected to column chromatography [silica; 1% methanol-dichloromethane] to give the title compound (180mg) as a pale yellow solid m.p. 105-106°. δ H (CDCl₃) 8.86 (1H, d, \downarrow 2.3Hz), 8.37 (1H, d, \downarrow 5.3Hz), 8.19 (1H, dd, \downarrow 9.0, 2.3Hz), 7.88-7.82 (2H, m), 7.72-7.68 (2H, m), 7.17 (1H, br s), 7.03-7.00 (3H, m), 6.64 (1H, d, \downarrow 9.0Hz), 3.90 (6H, s), 3.84 (3H, s), 3.86-3.80 (2H, m), 3.58-3.48 (4H, m), 2.53-2.42 (6H, m) and 1.95-1.89 (2H, m).

EXAMPLE 30

10 **4-(2-(4-N,N-Dimethylsulphamoyl)piperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine**

To a solution of the compound of Example 1 (300mg, 0.71mmol) and triethylamine (0.11ml, 0.8mmol) at room temperature was added dimethylsulphamoyl chloride (115mg, 0.8mmol) and the mixture stirred for 15 3h. The solvent was removed *in vacuo* and the residue subjected to column chromatography [silica 4% methanol-dichloromethane] to give the title compound (381mg) as a pale yellow solid m.p. 215-216°. δ H (CDCl₃) 8.88 (1H, d, \downarrow 2.3Hz), 8.39 (1H, d, \downarrow 5.3Hz), 8.23 (1H, dd, \downarrow 9.0, 2.3Hz), 7.23 (1H, br s), 7.04 (1H, d, \downarrow 5.3Hz), 7.01 (2H, s), 6.70 (1H, d, \downarrow 9.0Hz), 20 3.89 (6H, s), 3.84 (3H, s), 3.77-3.73 (4H, m), 3.38-3.35 (4H, m) and 2.87 (6H, s).

The following compounds of Examples 31-33 were prepared in a manner similar to the compound of Example 1.

25

EXAMPLE 31

N-(4-(2-N,N-Dimethylaminoethoxy)phenyl)-4-(2-(piperazin-1-yl)-pyridin-5-yl)-2-pyrimidineamine

From 4-(2-chloropyridin-5-yl)-N-(4-(2-N,N'-dimethylaminoethoxy)phenyl)-2-pyrimidineamine (410mg, 1.11mmol) and piperazine (286mg, 3.3mmol) to give the title compound (210mg) as a pale yellow solid m.p. 161-166°. δ H (CDCl₃) 8.87 (1H, d, \downarrow 2.4Hz), 8.33 (1H, d, \downarrow 5.3Hz), 8.15 (1H, dd, \downarrow 9.0, 2.4Hz), 7.54 (2H, m), 7.18 (1H, s), 6.98 (1H, d, \downarrow 5.3Hz), 6.93 (2H, m), 6.68 (1H, d, \downarrow 9.0Hz), 4.07 (2H, t, \downarrow 5.7Hz), 3.64 (4H, m), 2.99 (4H, m), 35 2.74 (2H, t, \downarrow 5.7Hz) and 2.35 (6H, s).

The pyrimidineamine used as starting material was prepared in a manner similar to the analogous starting material in Example 1, from Intermediate 2 (0.79g, 3.7mmol), 4-(2-N',N'-dimethylaminoethoxy)phenylguanidine dinitrate (1.3g, 3.7mmol) and powdered sodium hydroxide (0.33g, 5 8.2mmol) to give the desired product (440mg) as a yellow solid, which was used without purification. δ H (DMSO) 9.56 (1H, s), 9.13 (1H, br s), 8.53 (2H, m), 7.66 (3H, m), 7.41 (1H, d, J 4.7Hz), 6.90 (2H, d, J 8.4Hz), 4.01 (2H, m), 2.62 (2H, m) and 2.20 (6H, s).

10 The guanidine was prepared by heating a solution of 4-(2-dimethylaminoethoxy)aniline (1.9g, 10.6mmol) and cyanamide (1.06g, 24.7mmol) in ethanol (5ml) at reflux, in the presence of concentrated nitric acid (1.4ml). After heating for 13h the solvent was removed under reduced pressure and the residue triturated with ethyl acetate and methanol to give the desired product (1.7g) as a grey solid m.p. 149-152 $^{\circ}$. δ H (d⁶ DMSO) 9.60 (0.6H, br s), 9.41 (1H, s), 7.20 (6H, m), 7.05 (2H, d, J 8.8Hz), 4.30 (2H, m), 3.50 (2H, m), 2.86 (6H, s).

EXAMPLE 32

N-(3,5-Dimethoxyphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidineamine

20 From 4-(2-chloropyridin-5-yl)-N-(3,5-dimethoxyphenyl)-2-pyrimidineamine (500mg, 1.46mmol) and piperazine (376mg, 4.4mmol) to give the title compound (380mg) as a white solid. δ H (d⁶ DMSO) 9.47 (1H, s), 8.91 (1H, d, J 2.4Hz), 8.42 (1H, d, J 5.3Hz), 8.24 (1H, dd, J 9.0, 2.4Hz), 7.29 (1H, d, J 2.4Hz), 7.13 (2H, m), 6.92 (1H, d, J 9.0Hz), 6.12 (1H, t, J 2.2Hz), 25 3.73 (6H, s), 3.55 (4H, m), 3.26 (1H, br s) and 2.78 (4H, m).

The pyrimidineamine used as starting material was prepared from Intermediate 2 (0.81g, 3.87mmol), 3,5-dimethoxyphenylguanidine nitrate (1.0g, 3.87mmol) and powdered sodium hydroxide (0.17g, 4.26mmol) to 30 give the desired product (690mg) as a pale yellow solid m.p. 176-177 $^{\circ}$. δ H (d⁶ DMSO) 9.72 (1H, s), 9.16 (1H, d, J 2.1Hz), 8.62 (1H, d, J 5.1Hz), 8.54 (1H, dd, J 8.4, 2.5Hz), 7.72 (1H, d, J 8.4Hz), 7.51 (1H, d, J 5.1Hz), 7.12 (2H, m), 6.15 (1H, t, J 2.3Hz) and 3.73 (6H, s).

35 The guanidine starting material was prepared from 3,5-dimethoxyaniline (2g, 13.0mmol) and cyanamide as described in Example 31 to give the desired product (2.3g) as a grey solid m.p. 181-183 $^{\circ}$. δ H (d⁶ DMSO) 9.56

(1H, s), 7.36 (4H, s), 6.41 (1H, d, \downarrow 2.0Hz), 6.38 (2H, d, \downarrow 2.0Hz) and 3.74 (6H, s).

EXAMPLE 33

5 **N-(3,4-Dimethoxyphenyl)-4-(2-piperazin-1-yl)pyridin-5-yl-2-pyrimidine-amine**

From 4-(2-chloropyridin-5-yl)-N-(3,4-dimethoxyphenyl)-2-pyrimidineamine (300mg, 0.87mmol) and piperazine (150mg, 1.75mmol) to give the title compound (203mg) as a beige solid m.p. 185-188°. δ H (d⁶ DMSO) 9.30

10 (1H, s), 8.90 (1H, d, \downarrow 2.3Hz), 8.38 (1H, d, \downarrow 5.3Hz), 8.23 (1H, dd, \downarrow 9.1, 2.6Hz), 7.55 (1H, d, \downarrow 2.3Hz), 7.28 (1H, dd, \downarrow 8.7, 2.4Hz), 7.23 (1H, d, \downarrow 5.3Hz), 6.89 (2H, m), 3.76 (3H, s), 3.71 (3H, s), 3.59 (4H, m) and 2.77 (4H, m).

The pyrimidineamine used as starting material was prepared from
15 **Intermediate 2** (0.81g, 3.87mmol), 3,4-dimethoxyphenylguanidine nitrate (1.0g, 3.87mmol) and powdered sodium hydroxide (0.17, 4.26mmol) to give the desired product (650mg) as a yellow solid. δ H (CDCl₃) 9.05 (1H, d, \downarrow 1.8Hz), 8.49 (1H, d, \downarrow 5.2Hz), 8.31 (1H, dd, \downarrow 8.3, 2.4Hz), 7.44 (1H, d, \downarrow 8.3Hz), 7.38 (1H, d, \downarrow 2.5Hz), 7.15 (1H, s), 7.08 (2H, m), 6.88 (1H, d, \downarrow 8.6Hz), 3.92 (3H, s) and 3.89 (3H, s).

The guanidine used as starting material was prepared from 4-aminoveratrole (3g, 19.6mmol) and cyanamide (1.2g, 29.4mmol) as described in Example 31 to give the desired product (3.73g) as a buff solid m.p. 236-238°. δ H (d⁶ DMSO) 9.37 (1H, br s), 7.19 (4H, br s), 6.98 (1H, d, \downarrow 8.6Hz), 6.83 (1H, d, \downarrow 2.4Hz), 6.76 (1H, dd, \downarrow 8.6, 2.4Hz) and 3.75 (6H, s).

EXAMPLE 34

30 **N-(3,5-Dimethylphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine bis trifluoroacetate**

A solution of 4-(2-(4-tert-butoxycarbonylpiperazin-1-yl)pyridin-5-yl)-N-(3,5-dimethylphenyl)-2-pyrimidineamine (45mg, 98mmol) in dichloromethane (1ml) at 0° was treated with trifluoroacetic acid (1 μ l) and stirred for 1h.

The solvent was removed under reduced pressure and the residue
35 triturated with ether to give the title compound (59mg) as a yellow solid m.p. 204-206°. δ H (d⁶ DMSO) 9.42 (1H, s), 8.96 (1H, d, \downarrow 2.3Hz), 8.85

(2H, br s), 8.45 (1H, d, \downarrow 5.2Hz), 8.33 (1H, dd, \downarrow 9.0, 2.3Hz), 7.44 (2H, s), 7.33 (1H, d, \downarrow 5.2Hz), 7.08 (1H, d, \downarrow 9.0Hz), 6.61 (1H, s), 3.85 (4H, m), 3.21 (4H, m) and 2.25 (6H, s).

The pyrimidineamine used as starting material in the above process was 5 prepared by the following method:

A mixture of 3,5-dimethylaniline (130mg, 1.06mmol) and 2-chloro-4-(2-(4-*tert*-butoxycarbonylpiperazin-1-yl)pyridin-5-yl)pyrimidine (100 mg, 0.27 mmol) in toluene (2ml) containing pyridine (0.1ml) was heated at reflux for 12h. The solvent was removed under reduced pressure and the residue 10 subjected to column chromatography [silica; ethyl acetate-hexane] to give the desired product (46mg) as a beige solid after recrystallisation from dichloromethane/hexane δ H (CDCl₃) 8.86 (1H, d, \downarrow 2.3Hz), 8.36 (1H, d, \downarrow 5.2Hz), 8.21 (1H, dd, \downarrow 9.0, 2.4Hz), 7.31 (3H, s), 7.01 (1H, d, \downarrow 5.2Hz), 6.68 (2H, m), 3.66 (4H, m), 3.55 (4H, m), 2.33 (6H, s) and 1.49 (9H, s).

15 The pyrimidine intermediate was prepared as follows:

A solution of 5-bromo-2-(4-*tert*-butoxycarbonylpiperazin-1-yl)pyridine (6.0g, 17.5mmol) in anhydrous THF (150ml) was cooled to -100° then treated dropwise with *tert*-butyllithium (22.0ml of a 1.7M solution in pentane, 37.4mmol) and the resulting thick yellow mixture stirred at -100° 20 for 30min. Zinc chloride (35.2 ml of a 0.5M solution in THF, 17.60mmol) was slowly added and the mixture stirred at -75° for 30min then allowed to warm to room temperature whereupon 2,4-dichloropyrimidine (3.98g, 26.71mmol) and tetrakis(triphenylphosphine)palladium(o) (1.0g, 0.86mmol) were added. The resulting mixture was refluxed for 5h then 25 allowed to cool to room temperature. Saturated aqueous ammonium chloride was added and the mixture was extracted three times with ethyl acetate. The organic phase was washed with brine then dried (MgSO₄) and evaporated to give the crude product which was recrystallised from ethyl acetate/hexane to give the desired pyrimidine (3.03g) as a beige solid m.p. 182-183°. δ H (CDCl₃) 8.82 (1H, d, \downarrow 2.5Hz), 8.49 (1H, d, \downarrow 5.4Hz), 8.24 (1H, dd, \downarrow 9.0, 2.5Hz), 7.49 (1H, d, \downarrow 5.4Hz), 6.68 (1H, d, \downarrow 9.0Hz), 3.69 (4H, m), 3.56 (4H, m) and 1.48 (9H, s).

30 The pyridine intermediate was prepared by treating a suspension of 5-bromo-2-(piperazin-1-yl)pyridine (7.0g, 28.9mmol) with di-*tert*-butyldicarbonate (6.30g, 28.9mmol) and the resulting mixture stirred for 2h. The solvent was removed under reduced pressure to give the desired 35

product (8.76g as a beige solid after recrystallisation from aqueous ethanol, m.p. 88-90°. δ H (CDCl₃) 8.18 (1H, d, J 2.5Hz), 7.52 (1H, dd, J 9.0, 2.5Hz), 6.52 (1H, d, J 9.0Hz), 3.50 (8H, m) and 1.47 (9H, s).

The 5-bromo-2-(piperazin-1-yl)pyridine was prepared by heating a mixture 5 of 2,5-dibromopyridine (10.0g, 42.4mmol) and piperazine (7.98g, 92.8mmol) as a melt at 125° for 3h. On cooling to room temperature the mixture was triturated with methanol-dichloromethane to afford the desired product (7.0g) as a beige solid. δ H (CDCl₃) 8.18 (1H, d, J 2.1Hz), 7.25 (1H, dd, J 9.1, 2.1Hz), 6.52 (1H, d, J 9.1Hz), 3.47 (4H, m), 2.97 (4H, m) 10 and 1.75 (1H br s).

EXAMPLES 35-65

The compounds of Examples 35-65 were prepared by solid-phase synthesis using the following derivatised resin:

15 **4-(5-(2-Chloropyrimidin-4-yl)(pyridin-2-yl)piperazine-1-carbonate**
Derivatised Resin (1)

To a solution of 2-chloro-4-(2-(4-*tert*-butoxycarbonylpiperazin-1-yl)pyridin-5-yl)-pyrimidine (2.81g, 7.5mmol) in dichloromethane (25ml) was added trifluoroacetic acid (10mls) and the mixture stirred for 4 hours at room 20 temperature. The solution was evaporated to dryness *in vacuo* and re-evaporated from ether (25mls) twice to yield a yellow solid containing 2-chloro-4-(2-(piperazin-1-yl)pyridin-5-yl)pyrimidine.

25 To a suspension of Fluka Tentagel-S-PHB Resin (10.0g, 2.4mmol eq.) in dichloromethane was added triethylamine (5mls), 4-nitrophenylchloroformate (2.01g, 10mmol) and the mixture swirled at room temperature for 17 hours. The resin was filtered under a stream of nitrogen and washed sequentially with DMF and dichloromethane. The resulting derivatised resin was dried under a stream of nitrogen for 30 minutes and suspended 30 in DMF (40mls). Triethylamine (5ml), 4-dimethylaminopyridine (about 100mg) and the yellow solid prepared above were added and the mixture swirled at room temperature for 48 hours. The resin was filtered and washed thoroughly with DMF (2 x 50mls) and dichloromethane (4 x 50mls). The resin was suspended in methanol/water (9:1) (100ml) 35 containing lithium hydroxide (1%) for ten minutes. The resin was filtered and washed successively with methanol, dichloromethane/ methanol (1:1)

and dichloromethane and air dried on the filter funnel to give the desired derivatised resin (1).

5 The 2-chloro-4-(2-(4-*tert*-butoxycarbonylpiperazin-1-yl)pyridin-5-yl)-pyrimidine used as starting material in the above preparation was prepared as follows:

10 A mixture of 2,5-dibromopyridine (10.00g, 42.21mmol) and piperazine (7.98g, 92.79mmol) were heated as a melt at 125° for 3h. On cooling to room temperature the mixture was triturated with 10% methanol-dichloromethane and filtered. The filtrate was evaporated and the residue subjected to column chromatography (silica, 5-8% methanol-dichloromethane) to afford the 5-bromo-2-(1-piperazinyl)pyridine (7.00g) as a beige solid δ_H (CDCl₃) 2.75 (1H, br s), 2.97 (4H, m), 3.47 (4H, m), 15 6.52 (1H, d, $\underline{\Delta}$ 9.1Hz), 7.52 (1H, dd, $\underline{\Delta}$ 9.1, 2.1Hz), and 8.18 (1H, d, $\underline{\Delta}$ 2.1Hz).

20 A suspension of the bromopyridine (7.00g, 28.91mmol) in THF (60ml) at room temperature was treated with di-*tert*-butyldicarbonate (6.30g, 28.90mmol) and the resulting mixture stirred for 2h, then evaporated and the crude product purified by recrystallisation (ethanol-water) to afford the 5-Bromo-2-(4-*tert*-butoxycarbonylpiperazin-1-yl)pyridine (8.76g) as a beige solid m.p. 88-90°. δ_H (CDCl₃) 1.47 (9H, s), 3.50 (8H, m), 6.52 (1H, d, $\underline{\Delta}$ 9.0Hz), 7.52 (1H, dd, $\underline{\Delta}$ 9.0, 2.5Hz) and 8.18 (1H, d, $\underline{\Delta}$ 2.5 Hz).

25 A solution of the protected bromopyridine (6.00g, 17.50mmol) in anhydrous THF (150ml) was cooled to -100° (liquid nitrogen-diethyl ether) then treated dropwise with *tert*-butyllithium (22.0ml of a 1.7M solution in pentane, 37.40mmol) and the resulting thick yellow mixture stirred at -100° for 30min. Zinc chloride (35.2ml of a 0.5M solution in THF, 17.60mmol) was slowly added and the mixture stirred at -75° for 30min then allowed to 30 warm to room temperature whereupon 2,4-dichloropyrimidine (3.98g, 26.71mmol) and tetrakis(triphenylphosphine)-palladium(o) (1.00g, 0.86mmol) were added. The resulting mixture was refluxed for 5h then allowed to cool to room temperature. Saturated aqueous ammonium chloride was added and the mixture was extracted three times with ethyl acetate. The organic phase was washed with brine then dried (MgSO₄) 35 and evaporated to give a crude product which was purified by

recrystallisation (ethyl acetate-hexane) to afford the desired chloropyridine (3.03g) as a beige solid m.p. 182-183°. δ_H (CDCl₃) 1.48 (9H, s), 3.56 (4H, m), 3.69 (4H, m), 6.68 (1H, d, J 9.0Hz), 7.49 (1H, d, J 5.4Hz), 8.24 (1H, dd, J 2.5, 9.0Hz), 8.49 (1H, d, J 5.4Hz) and 8.82 (1H, d, J 2.5Hz).

5

EXAMPLE 35

4-(2-(Piperazin-1-yl)pyridin-5-yl)-N-phenyl-2-pyrimidineamine

To the derivatised resin (1), (0.1g), prepared above, in a ptfe-fritted reaction well was added aniline (120 μ l) and mesitylene (1.0ml). The 10 reaction vessel was heated to 140°C for 18hr then cooled to room temperature. The reaction vessel was drained and the resin was washed with three portions of methanol followed by six portions of methanol/dichloromethane (1:1) and six portions of dichloromethane.

15 The resin was suspended in dichloromethane (0.5ml) and trifluoroacetic acid (0.5ml) and swirled at room temperature for 2.5h, filtered and washed with dichloromethane (2 portions of 0.5mls) and the filtrate evaporated *in vacuo* to give the title compound.
HPLC (Conditions A) Retention time 4.085mins
20 HPLC-MS (conditions B) Retention time 6.38mins, (M+H)⁺ =333

The HPLC and HPLC-MS conditions were as follows:

HPLC Conditions A

HPLC was performed on a Waters Millenium system with a Waters 996A 25 photodiode array detector. A Zorbax RX C18 15x0.46cm: 5mm particle size column, running a gradient of 90% [0.1% TFA water] 10% [0.1%TFA acetonitrile] to 10% [0.1% TFA water] 90% [0.1%TFA acetonitrile], at 1.2ml/min with a run time of 13 minutes at ambient temperature.

30 HPLC-MS Conditions B

HPLC-MS was performed on a Hewlet Packard 1050 using a Zorbax-SB C18, 150x2.1mm column at 60°C, running a gradient of 15% [0.1%formic acid in acetonitrile], 85% [90%water:10%acetonitrile 0.1%formic acid] to 70% [0.1%formic acid in acetonitrile], 30% [90%water:10%acetonitrile 35 0.1%formic acid] at a flow rate of 200ml/min. MS acquired in centroid at 2 cone voltages (27V and 60V), on a Micromass Quattro (triple quadrupole

mass spectrometer) in positive ion electrospray mode of ionisation, scanning from 120-700amu.

The following compounds of Examples 36-65 were prepared in a similar
5 manner to the compound of Example 35, each using the starting material shown. As in Example 35, the quantities of resin and starting material employed were maintained such that the starting material was in excess. The HPLC and HPLC-MS conditions referred to in each example are those just described.

10

EXAMPLE 36

4-(2-(Piperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trifluorophenyl)-2-pyrimidineamine

3,4,5-trifluoroaniline gave the title compound.

15 HPLC (Conditions A) Retention time 5.437mins

HPLC-MS (Conditions B) Retention time 12.94mins, $(M+H)^+ = 387$

EXAMPLE 37

N-(4-Methoxyphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine

4-methoxyaniline gave the title compound

HPLC (Conditions A) Retention time 4.00mins

HPLC-MS (Conditions B) Retention time 5.29mins, $(M+H)^+ = 363$

25 **EXAMPLE 38**

N-(2,4-Dimethoxyphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidineamine

2,4-dimethoxyaniline gave the title compound

HPLC (Conditions A) Retention time 4.072mins

30 HPLC-MS (Conditions B) Retention time 6.31mins, $(M+H)^+ = 393$

EXAMPLE 39

N-(4-Carboxamidophenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidineamine

35 4-aminobenzamide gave the title compound

HPLC (Conditions A) Retention time 3.547mins

HPLC-MS (Conditions B) Retention time 3.53mins, $(M+H)^+ = 376$

EXAMPLE 40

5 **N-(4-Phenoxyphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine**

4-phenoxyaniline gave the title compound

HPLC (Conditions A) Retention time 5.425mins

HPLC-MS (Conditions B) Retention time 13.36mins, $(M+H)^+ = 425$

10 **EXAMPLE 41**

N-(3,4-Dimethylphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine

3,4-dimethylaniline gave the title compound

HPLC (Conditions A) Retention time 4.682mins

15 HPLC-MS (Conditions B) Retention time 11.59mins, $(M+H)^+ = 362$

EXAMPLE 42

N-(4-Hydroxyphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine

20 4-hydroxyaniline gave the title compound

HPLC (Conditions A) Retention time 3.348mins

HPLC-MS (Conditions B) Retention time 3.53mins, $(M+H)^+ = 349$

EXAMPLE 43

25 **N-(3-Nitrophenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidineamine**

3-nitroaniline gave the title compound

HPLC-MS (Conditions B) Retention time 11.0mins, $(M+H)^+ = 378$

EXAMPLE 44

30 **N-(4-Chlorophenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine**

4-chloroaniline gave the title compound

HPLC (Conditions A) Retention time 4.927mins

HPLC-MS (Conditions B) Retention time 12.18mins, $(M+H)^+ = 367/369$

EXAMPLE 45**N-(1-Naphthyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidineamine**

1-naphthylamine gave the title compound

5 HPLC (Conditions A) Retention time 4.493mins

HPLC-MS (Conditions B) Retention time 10.83mins, $(M+H)^+ = 383$

EXAMPLE 46**N-(3-Hydroxymethylphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-**

10 **pyrimidineamine**

3-hydroxymethylaniline gave the title compound

HPLC (Conditions A) Retention time 3.553mins

HPLC-MS (Conditions B) Retention time 3.86mins, $(M+H)^+ = 363$

15 **EXAMPLE 47**

N-(5-Indanyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine

5-aminoindane gave the title compound

HPLC (Conditions A) Retention time 4.827mins

HPLC-MS (Conditions B) Retention time 12.35mins, $(M+H)^+ = 373$

20

EXAMPLE 48**N-(3-Carboxyphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine**

3-aminobenzoic acid gave the title compound

25 HPLC (Conditions A) Retention time 4.028mins

HPLC-MS (Conditions B) Retention time 4.79mins, $(M+H)^+ = 377$

EXAMPLE 49**N-(4-N,N-Dimethylaminophenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidineamine**

4-N,N-dimethylaminoaniline gave the title compound

HPLC (Conditions A) Retention time 3.337mins

HPLC-MS (Conditions B) Retention time 3.44mins, $(M+H)^+ = 376$

EXAMPLE 50**N-(3-Chloro-4-fluorophenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidineamine**

3-Chloro-4-fluoraniline gave the title compound

5 HPLC (Conditions A) Retention time 5.155mins

HPLC-MS (Conditions B) Retention time 12.52mins, $(M+H)^+ = 385/387$

EXAMPLE 51**N-(Benzo[d][1,3]dioxol-5-yl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidineamine**

10 benzo[d][1,3]dioxan-5-amine gave the title compound

HPLC (Conditions A) Retention time 4.040mins

HPLC-MS (Conditions B) Retention time 5.63mins, $(M+H)^+ = 377$

15 **EXAMPLE 52**

4-(2-(Piperazin-1-yl)pyridin-5-yl)-N-(3-(1,1,2,2-tetrafluoroethoxy)-phenyl)-2-pyrimidineamine

3-(1,1,2,2-Tetrafluoroethoxy)aniline gave the title compound

HPLC (Conditions A) Retention time 5.473mins

20 HPLC-MS (Conditions B) Retention time 13.02mins, $(M+H)^+ = 449$

EXAMPLE 53**N-(3-Chlorophenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine**

25 3-chloroaniline gave the title compound

HPLC (Conditions A) Retention time 5.023mins

HPLC-MS (Conditions B) Retention time 12.35mins, $(M+H)^+ = 367/369$

EXAMPLE 54**N-(3-Bromophenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine**

3-bromoaniline gave the title compound

HPLC (Conditions A) Retention time 5.132mins,

HPLC-MS (Conditions B) Retention time 12.60mins, $(M+H)^+ = 411/413$

EXAMPLE 55**N-(3-Methoxyphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine**

3-methoxyaniline gave the title compound

5 HPLC (Conditions A) Retention time 4.320mins

HPLC-MS (Conditions B) Retention time 7.39mins, $(M+H)^+ = 363$

EXAMPLE 56**N-(3-Fluorophenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine**

3-fluoroaniline gave the title compound

HPLC (Conditions A) Retention time 4.658mins

HPLC-MS (Conditions B) Retention time 9.78mins, $(M+H)^+ = 351$

15 **EXAMPLE 57**

N-(3-Methylphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine

3-methylaniline gave the title compound

HPLC (Conditions A) Retention time 4.428mins,

20 HPLC-MS (Conditions B) Retention time 9.07mins, $(M+H)^+ = 347$

EXAMPLE 58**N-(3,4-Dimethoxyphenylmethyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine**

25 3,4-dimethoxyaniline gave the title compound

HPLC (Conditions A) Retention time 3.795mins

HPLC-MS (Conditions B) Retention time 3.74mins, $(M+H)^+ = 407$

EXAMPLE 59**N-(4-Butoxyphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine**

4-butoxyaniline gave the title compound

HPLC (Conditions A) Retention time 5.302mins

HPLC-MS (Conditions B) Retention time 13.10mins, $(M+H)^+ = 405$

EXAMPLE 60**N-(4-Fluorophenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-amine**

4-fluoroaniline gave the title compound

5 HPLC (Conditions A) Retention time 4.275mins

HPLC-MS (Conditions B) Retention time 7.22mins, $(M+H)^+ = 351$

EXAMPLE 61**N-(4-Ethylphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidine-**

10 **amine**

4-ethylaniline gave the title compound

HPLC (Conditions A) Retention time 4.828mins

HPLC-MS (Conditions B) Retention time 12.14mins, $(M+H)^+ = 361$

15 **EXAMPLE 62**

4-(2-(Piperazin-1-yl)pyridin-5-yl)-N-(4-trifluoromethoxyphenyl)-2-pyrimidineamine

4-trifluoromethoxyaniline gave the title compound

HPLC (Conditions A) Retention time 5.413mins

20 HPLC-MS (Conditions B) Retention time 13.27mins, $(M+H)^+ = 417$

EXAMPLE 63**4-(2-(Piperazin-1-yl)pyridin-5-yl)-N-(3-trifluoromethoxyphenyl)-2-pyrimidineamine**

25 3-trifluoromethoxyaniline gave the title compound

HPLC (Conditions A) Retention time 5.490mins

HPLC-MS (Conditions B) Retention time 13.27mins, $(M+H)^+ = 417$

EXAMPLE 64**30 N-(4-N,N-Diethylaminophenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidineamine**

4-N,N-diethylaminoaniline gave the title compound

HPLC (Conditions A) Retention time 3.615mins

HPLC-MS (Conditions B) Retention time 3.53mins, $(M+H)^+ = 404$

EXAMPLE 65**N-(2,3-Dimethoxyphenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidineamine**

2,3-dimethoxyaniline gave the title compound

5 HPLC (Conditions A) Retention time 4.322mins

HPLC-MS (Conditions B) Retention time 9.03mins, $(M+H)^+ = 393$

EXAMPLE 66**4-(2-(3(S)-Ethylpiperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxy-phenyl)-2-pyrimidineamine**

From **Intermediate 1** (555mg, 1.5mmol) and 2(S)-ethylpiperazine (500mg, 4.38mg) to give the title compound (445mg) as a yellow solid m.p. 82-83°. δ H (CDCl₃) 8.87(1H, d, \downarrow 8.7Hz), 8.20 (1H, dd, \downarrow 9.0, 2.5Hz), 7.31 (1H, s), 7.03 (1H, d, \downarrow 5.3Hz), 7.01 (2H, s), 6.66 (1H, d, \downarrow 8.6 Hz), 4.34-4.22 (2H, m), 3.88 (6H, s), 3.83 (3H, s), 3.16-3.11(1H, m), 3.03-2.86 (2H, m), 2.68-2.56 (2H, m), 1.79 (1H, br s), 1.57-1.42 (2H, m) and 1.01 (3H, t, \downarrow 7.5Hz). (S)-2-Ethylpiperazine was prepared by treating a suspension of (S)-3-ethylpiperazine-2,5-dione (4.5g, 31.7mmol) in dry THF (175ml) with LiAlH₄ (3.61g, 95mmol) in a portionwise manner at 0°. The reaction was then heated at reflux for 18h and on cooling a 2M sodium hydroxide solution was added until a precipitate appeared. The reaction was filtered, the precipitate washed with hot ethyl acetate and the combined filtrate and washings concentrated under reduced pressure. The resulting white solid was sublimed under vacuum to give the desired product (1.1g) as a white solid, m.p. 66-67°.

(S)-3-Ethylpiperazine-2,5-dione was prepared by adding a solution of (S)-4-ethyloxazolidine-2,5-dione (6.0g, 46.5 mmol) in THF (75ml) to a mixture of glycine methyl ester hydrochloride (6.13g) and triethylamine (15.3ml, 109.8 mmol) in chloroform at -60°. The reaction was allowed to warm to room temperature over 2.5h. The reaction was filtered and the filtrate concentrated under reduced pressure, re-dissolved in toluene (100ml) and heated at reflux for 15h. The reaction was cooled in an ice-bath and the resulting precipitate collected and subjected to column chromatography to give the desired product (4.7g) as a white solid, m.p. 170-171°.

EXAMPLE 67**4-(2-(5-Methyl-1,4-diazacycloheptan-1-yl)pyridin-5-yl)-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine**

From **Intermediate 1** (200mg,0.54mmol) and 5-methyl-1,4-diazacycloheptane (500mg,4.38mmol) to give the title compound (160mg) as a pale yellow solid, m.p. 104-106°. δ H(CDCl₃) 8.87 (1H, d, J 2.3Hz), 8.36 (1H, d, J 5.3Hz), 8.18 (1H, dd, J 9.0,2.3Hz), 7.20 (1H, s), 7.03 (1H, d, J 5.3Hz), 7.01 (2H, s), 6.54 (1H, d, J 9.0Hz), 4.17-4.08 (1H, m), 3.90-3.85 (1H, m), 3.89 (6H, s), 3.84 (3H, s), 3.72-3.60 (2H, m), 3.34-3.28 (1H, m), 3.11-3.02 (1H, m), 2.96-2.88 (1H, m), 2.17-2.06 (1H, m) and 1.82-1.73 (1H, m).

5-Methyl-1,4-diazacycloheptane was prepared by hydrogenation of a solution of 1,4-dibenzyl-5-methyldiazacycloheptane in ethanol (40ml) over 10% palladium on carbon at 20psi and 55° for 18h. The catalyst was removed by filtration and the filtrate concentrated under reduced pressure

10 to give the desired product (0.5g) as a colourless gum. δ H (CDCl₃) 2.90-2.60(9H, m), 1.73-1.65 (1H, m), 1.32-1.22 (1H, m) and 0.97 (3H, d, J 8.0Hz).

EXAMPLE 68**20 N-(3,4,5-Trichlorophenyl)-4-(2-(piperazin-1-yl)pyridin-5-yl)-2-pyrimidineamine**

A solution of 4-(2-(4-allyloxycarbonylpiperazin-1-yl)pyridin-5-yl)-N-(3,4,5-trichlorophenyl)-2-pyrimidineamine (170mg,0.33mmol) in dichloromethane and DMF (3ml,1:1 mixture) was stirred with acetic acid (1ml), dichloro-bis(triphenylphosphine)palladium (II) (15mg) and tri-n-butyltin hydride at room temperature for 5 min. The reaction was added to a saturated aqueous NaHCO₃ solution, which was extracted with ethyl acetate. The organic phase was dried (MgSO₄) and concentrated under reduced pressure. The residue was triturated with hexane and then subjected to column chromatography (silica gel with 1% ammonium hydroxide-8% methanol-dichloromethane) to give the title compound (60mg) as an off-white solid m.p. 208-211°. δ H(d₆ DMSO) 10.03(1H, s), 8.91 (1H, d, J 2.5Hz), 8.51 (1H, d, J 5.4Hz), 8.22 (1H, dd, J 9.1, 2.5Hz), 8.16 (2H, s), 7.43 (1H, d, J 5.4Hz), 3.56 (4H, m) and 2.78 (4H, m).

25 The pyrimidine starting material used in the above process was prepared by heating 4-(2-(allyloxycarbonylpiperazin-1-yl)pyridin-5-yl)-2-chloro-

30

35

pyrimidine (0.3g,8.3mmol) and 3,4,5-trichloroaniline (245mg, 8.3mmol in ethoxyethanol (2ml) at reflux for 24h. On cooling the resulting precipitate was collected and recrystallised from aqueous ethanol to give the desired product (77mg) as a beige solid,m.p.225-227°.

5

The chloropyrimidine was prepared by treating 2-chloro-4-(2-(4-tert-butoxycarbonylpiperazin-1-yl)pyridin-5-yl)pyrimidine in dichloromethane (15ml) with trifluoroacetic acid (15ml), at room temperature for 2h. The reaction was concentrated under reduced pressure and the resulting 10 residue suspended in dichloromethane (40ml) and saturated sodium hydrogen carbonate (40ml). To this was added allyl chloroformate (706mg,5.86mmol) and the reaction stirred at room temperature for 4h. The organic phase was evaporated and the residue recrystallised from hexane/ethyl acetate to give the desired material (1.72g) as a pale yellow 15 solid, m.p.136-138°.

BIOLOGICAL ACTIVITY

20 The following assays were used to demonstrate the activity and selectivity of compounds according to the invention. In each assay an IC₅₀ value for each test compound was determined. In each instance the IC₅₀ value was defined as the concentration of test compound required to inhibit 50% of the enzyme activity.

25 **p56^{lck} kinase assay**

The tyrosine kinase activity of p56^{lck} was determined using a RR-src peptide (RRLIEDNEYTARG) and [γ -³³P]ATP as substrates. Quantitation of the ³³P-phosphorylated peptide formed by the action of p56^{lck} was achieved using an adaption of the method of Geissler *et al* (J. Biol. Chem. 30 (1990) 265, 22255-22261).

All assays were performed in 20mM HEPES pH 7.5 containing 10mM MgCl₂, 10mM MnCl₂, 0.05% Brij, 1 μ M ATP (0.5 μ Ci[γ -³³P]ATP) and 0.8mg/ml RR-src. Inhibitors in dimethylsulphoxide (DMSO) were added 35 such that the final concentration of DMSO did not exceed 1%, and enzyme such that the consumption of ATP was less than 10%. After incubation at

30°C for 15min, the reaction was terminated by the addition of one-third volume of stop reagent (0.25mM EDTA and 33mM ATP in dH₂O). A 15µl aliquot was removed, spotted onto a P-30 filtermat (Wallac, Milton Keynes, UK), and washed sequentially with 1% acetic acid and dH₂O to remove 5 ATP. The bound ³³P-RR-src was quantitated by scintillation counting of the filtermat in a Betaplate scintillation counter (Wallac, Milton Keynes, UK) after addition of Meltilex scintillant (Wallac, Milton Keynes, UK). The dpm obtained, being directly proportional to the amount of ³³P-RR-src produced by p56^{lck}, were used to determine the IC₅₀ for each compound.

10

Zap-70 kinase assay

The tyrosine kinase activity of Zap-70 was determined using a capture assay based on that employed above for p56^{lck}. The RR-src peptide was replaced with polyGlu-Tyr (Sigma; Poole, UK) at a final concentration of 17 15 µg/ml. After addition of the stopped reaction to the filtermat, trichloroacetic acid 10% (w/v) was employed as the wash reagent instead of acetic acid and a final wash in absolute ethanol was also performed before scintillation counting.

20

Syk and Csk kinases assays

Compounds of the invention were assayed for syk kinase and csk kinase inhibitory activity in a similar manner to the ZAP-70 assay.

EGFr kinase assay

25 The tyrosine kinase activity of the EGF receptor (EGFr) was determined using a similar methodology to the p56^{lck} kinase assay, except that the RR-src peptide was replaced by a peptide substrate for EGFr obtained from Amersham International plc (Little Chalfont, UK) and used at the manufacturer's recommended concentration.

30

Protein kinase C assay

Inhibitor activity against protein kinase C (PKC) was determined using PKC obtained from Sigma Chemical Company (Poole, UK) and a commercially available assay system (Amersham International plc, Little 35 Chalfont, UK). Briefly, PKC catalyses the transfer of the γ -phosphate (³²p) of ATP to the threonine group on a peptide specific for PKC.

Phosphorylated peptide is bound to phosphocellulose paper and subsequently quantified by scintillation counting.

p34 Cdc2 kinase assay


5 The tyrosine kinase activity of p34cdc2 was determined using a commercially available enzyme assay (Amersham International plc, Little Chalfont, UK; product code RPNQ0170).

10 In the above assays, compounds according to the invention selectively inhibit ZAP-70 and syk kinases. Thus, for example, the most active compounds of the Examples each have an IC₅₀ value against ZAP-70 of below 500nM. When compared with IC₅₀ values obtained with the other enzymes above the advantageous selectivity of the compounds becomes apparent. The most selective compounds have selectivities (as 15 determined by the ratio of IC₅₀ values) in excess of 100x against p56^{lck}, EGFr, csk, protein kinase C and p34cdc2.

CLAIMS

1. A compound of formula (1)

5



wherein Ar is an optionally substituted aromatic group;

10 R² is a hydrogen or halogen atom or a group -X¹-R^{2a} where X¹ is a direct bond or a linker atom or group, and R^{2a} is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R³ is an optionally substituted heterocycloalkyl group; and the salts, solvates, hydrates and N-oxides thereof.


15 2. A compound according to Claim 1 wherein R² is a hydrogen atom.

3. A compound according to Claim 2 wherein Ar is an optionally substituted phenyl group.

20 4. A compound according to Claim 3 wherein R³ is an optionally substituted azetidinyl, pyrrolidinyl, piperazinyl, homopiperazinyl, morpholinyl or thiomorpholinyl group.

5. A compound of formula (1a):


25



and the salts, solvates, hydrates and N-oxides thereof
whererein Ar, R² and R³ are as defined in any one of Claims 1 to 4.

5


6. A compound according to Claim 5 which has the formula (1b):



10 and the salts, solvates, hydrates and N-oxides thereof.

7. A compound according to any one of the preceding claims whererein R³ is an optionally substituted piperazine or homopiperazine group.

15 8. A pharmaceutical composition comprising a compound of formula (1):



wherein Ar is an optionally substituted aromatic group;
R² is a hydrogen or halogen atom or a group -X¹-R^{2a} where X¹ is a direct bond or a linker atom or group, and R^{2a} is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group;
5 R³ is an optionally substituted heterocycloalkyl group;
and the salts, solvates, hydrates and N-oxides thereof; together with one or more pharmaceutically acceptable carriers, excipients or diluents.

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/GB 97/02949

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D401/04 C07D401/14 A61K31/505

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 09853 A (CIBA-GEIGY) 13 April 1995 see page 1 - page 14; claims ---	1-8
A	WO 95 09847 A (CIBA-GEIGY) 13 April 1995 see page 1 - page 7; claim 6 ---	1-8
P, A	WO 97 19065 A (CELLTECH) 29 May 1997 see page 74 - page 80; claims; examples 69-86 -----	1-8

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

1	Date of the actual completion of the international search 3 March 1998	Date of mailing of the international search report 14/04/1998
	Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Francois, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int	National Application No
PCT/GB 97/02949	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9509853 A	13-04-95	AU 7697794 A		01-05-95
		CA 2148928 A		13-04-95
		CN 1115982 A		31-01-96
		CZ 9501722 A		13-03-96
		EP 0672041 A		20-09-95
		FI 952607 A		29-05-95
		HU 72609 A		28-05-96
		JP 8504215 T		07-05-96
		NO 952132 A		30-05-95
		NZ 273617 A		26-11-96
		PL 309225 A		02-10-95
		ZA 9407657 A		03-04-95
-----	-----	-----	-----	-----
WO 9509847 A	13-04-95	AU 7697694 A		01-05-95
		CA 2148931 A		13-04-95
		EP 0672035 A		20-09-95
		JP 8503971 T		30-04-96
		US 5612340 A		18-03-97
-----	-----	-----	-----	-----
WO 9719065 A	29-05-97	AU 7631496 A		11-06-97
-----	-----	-----	-----	-----